WO1993023069A1 - Health supplements containing phyto-oestrogens, analogues or metabolites thereof - Google Patents
Health supplements containing phyto-oestrogens, analogues or metabolites thereof Download PDFInfo
- Publication number
- WO1993023069A1 WO1993023069A1 PCT/AU1993/000230 AU9300230W WO9323069A1 WO 1993023069 A1 WO1993023069 A1 WO 1993023069A1 AU 9300230 W AU9300230 W AU 9300230W WO 9323069 A1 WO9323069 A1 WO 9323069A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- phyto
- oestrogen
- oestrogens
- health
- supplement
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L11/00—Pulses, i.e. fruits of leguminous plants, for production of food; Products from legumes; Preparation or treatment thereof
- A23L11/05—Mashed or comminuted pulses or legumes; Products made therefrom
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L11/00—Pulses, i.e. fruits of leguminous plants, for production of food; Products from legumes; Preparation or treatment thereof
- A23L11/05—Mashed or comminuted pulses or legumes; Products made therefrom
- A23L11/07—Soya beans, e.g. oil-extracted soya bean flakes
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
- A23L33/11—Plant sterols or derivatives thereof, e.g. phytosterols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
Definitions
- This invention relates to natural products containing phyto-oestrogens, or phyto-oestrogen metabolites, which have various beneficial physiological effects in man, and which have a variety of uses, such as to promote good health and as a dietary additive, for example.
- the particular product in accordance with the invention is an extract of certain plants with the particular purpose of enrichment for phyto-oestrogens, both in their natural state and their closely related derivatives and metabolites.
- Plants which are used as foodstuffs or medicinal herbs contain a wide variety of chemicals which are assimilated into the body following ingestion. Some of these chemicals are important nutrients for man and animals (e.g. fats, carbohydrates, proteins, vitamins, minerals) while others have none, or little or no known nutritional value. The phyto-oestrogens hitherto have fallen into this latter category of no known nutritional value.
- phyto-oestrogens There are 3 principal classes of phyto-oestrogens, viz. isoflavones, lignans, and coumestans.
- the isoflavones are thought to have a broad range of biological functions in plants, although these are poorly understood.
- two particular functions are recognised - (a) as phyto- alexin or stressor chemicals which are secreted by the plant in response to attack by parasites such as insects, fungi, viruses, etc and which display activity against these parasites, and (b) chemicals which encourage colonisation of nitrogen-fixing bacteria on the roots of legumes.
- the biological functions in plants of the lignans and coumestans is not generally understood.
- phyto-oestrogens are as follows.
- Type 1 phyto-oestrogens - (isoflavones)
- Isoflavones appear to be widely distributed in the plant kingdom and over 700 different isoflavones are described. However, the isoflavones which display oestrogenic activity belong to a small sub-group and are restricted almost exclusively to the Leguminosae family.
- the known oestrogenic isoflavones are daidzein, formononetin, genistein and biochanin A.
- the total levels of the oestrogenic isoflavones range between about 40 and 300 g per 100 g dry weight
- isoflavones occur principally as glycosides. Following ingestion by man and animals, the glycoside moiety is hydrolysed free by a combination of gastric acid hydrolysis and fermentation by intestinal bacteria. Some of the isoflavones in the aglucone form are absorbed directly and circulate in the blood, while the remainder are metabolised by intestinal fermentation to a variety of compounds which are also absorbed. The absorbed isoflavones and their metabolites appear to undergo little or no further metabolism in the body, being readily transported in the bloodstream, and ultimately being excreted in the urine.
- Lignans are widely distributed in the plant kingdom. Over one hundred lignans are described and they are reported in common human foodstuffs such as cereals, fruits and vegetables. Oilseeds such as flax (linseed) have the highest known levels at 20-60 mg/100 g dry weight, while cereals and legumes have much lower levels at 0.3-0.6 mg/10& g, and vegetables even lower levels at 0J-0.2 mg/100 g. The most common lignan described is metairesinol. Dietary lignans also appear to be metabolised fairly efficiently within the gut by bacterial fermentation, yielding metabolites such as enterodiol and enterolactone which are absorbed into the bloodstream and excreted in the urine.
- Type 3 phyto-oestrogens (coumestans).
- oestrogenic coumestans appear to have a relatively restricted distribution in plants and generally occur at much lower levels. Alfalfa, ladino clover and some other fodder crops such as barrel medic may have significant levels and have been reported to cause reproductive dysfunction in grazing animals.
- the important sources of coumestans are sprouts of soya and alfalfa where levels up to 7 mg/lOOg dry weight are reported.
- Whole soyabeans and other common foodstuff legumes contain levels of approx. 0J2 mg/100 g dry weight and most of that is concentrated in the seed hull which commonly is removed in the preparation of human foodstuffs.
- phyto-oestrogens appear to act at the cellular level in a similar manner, that is through interaction with cell surface oestrogen receptors.
- oestrogens In the body, naturally-occurring oestrogens circulating in the blood largely exert their activity by interaction with oestrogen receptors on cell surfaces; such interactions then triggering a particular biological function of that particular cell.
- Phyto-oestrogens are able to bind to those oestrogen Teceptors because the structure of these compounds so closely resembles the endogenous oestrogens, but unlike the animal oestrogens, phyto-oestrogens only weakly activate the oestrogen receptor.
- phyto-oestrogens are held to be competitive inhibition of endogenous oestrogens.
- another more direct effect is the stimulation of synthesis of SHBG in the liver, as occurs with orally administered synthetic steroidal oestrogens.
- High levels of dietary phyto-oestrogens are thought to be responsible for the higher SHBG levels seen in vegetarians and in cultures maintaining traditional (high legume-containing) diets.
- dietary phyto-oestrogens can have profound physiological effects.
- An example of this is sheep and cattle grazing pastures containing a high proportion of subterranean clover or red clover which can contain levels of phyto-oestrogens as high as 5% of the dry weight of the plant.
- sheep and cattle grazing pastures containing a high proportion of subterranean clover or red clover which can contain levels of phyto-oestrogens as high as 5% of the dry weight of the plant.
- phyto-oestrogens Such high dietary levels of phyto-oestrogens, however, are rare. It is far more common that most animal and human diets contain low to moderate levels of phyto-oestrogens, and there is growing epidemiological evidence that such levels have a beneficial effect on human health.
- the principal phyto-oestrogens consumed are isoflavones because of the generally high reliance on legumes (also known as pulses) as a source of protein.
- the general consumption rates (g day/person) for legumes for different regions currently are approximately: Japan (50-90), India (40-80), South America (30- 70), North Africa (40-50), Central/Southern Africa (20-50) and Southern Mediterranean (30- 60).
- Legumes also are a source of lignans and, to a much lesser extent, coumestans, and the additional cereal and vegetables in the diet would also boost the lignan intake.
- the isoflavone intake in these traditional cultures with high legume consumption would typically be much in excess of either lignan or coumestan intake.
- the major types of legumes used in traditional diets include soya, chickpeas, lentils, ground nuts, beans (e.g. broad, haricot, kidney, lima, navy), and grams (bengal, horse and green).
- the typical phyto- oestrogen intake (mg/day) for different regions can be calculated approximately as
- regions which have maintained traditional diets have a higher average daily intake of phyto-oestrogens, particularly isoflavones, compared to western countries.
- People in communities such as Japan or developing countries with high legume intake excrete substantially higher phyto-oestrogen metabolites in their urine compared to people in Western countries.
- vegetarians also excrete higher phyto-oestrogen metabolite levels than do those consuming a more typical, omnivorous Western diet.
- both the rate of production and/or the function of endogenous oestrogens may be either dependent upon or influenced by the presence of phyto-oestrogens in the body. It follows therefore that a relative deficiency of dietary phyto-oestrogens could be expected to lead to an imbalance of endogenous oestrogen metabolism.
- SHBG phyto-oestrogens
- isoflavones are potent stimulators of SHBG synthesis, they only weakly bind to SHBG, so that the increased SHBG levels resulting from the dietary isoflavones are largely available for binding to endogenous oestrogens.
- legumes such as soya and various pulses have been shown to have a hypocholesterolaemic effect in humans; this effect has not been ascribed to phyto-oestrogens, although purified isoflavones do have a hypocholesterolaemic effect in animals with artificially-induced hypercholesterolaemia.
- An alternative strategy is to make available either (i) phyto-oestrogens in a purified form, or (ii) foodstuffs which are enriched for phyto-oestrogens.
- the phyto-oestrogen could be added to the diet in a convenient form as a supplement without requiring any substantive change to the diet.
- the present invention concerns a health supplement specifically enriched for isoflavones selected from genistein, daidzein, formononeti ⁇ and biochanin A, or their natural glycoside form, or their analogues, in sufficient amounts to improve the health of a human.
- the supplement contains an excipient, a diluent, a carrier or the like, or else the supplement is mixed with food or can be consumed directly.
- foodstuffs are readily available, have no known toxic components, and are rich sources of isoflavones; such foodstuffs preferably being red clover or soya.
- the ratio of genistein and/or it methylated derivative biochanin A to daidzein and/or its methylated derivative formononetin is between 1:2 to 2:1.
- Other plant components with oestrogenic activity including lignans, coumestans and flavones may also be present in the extract, but it is held that these are of secondary importance to the predominant isoflavones.
- phyto-oestrogens is used hereafter to indicate a predominance of isoflavones with lesser amounts of lignans, coumestans and flavones.
- the invention also concerns a method of improving the health of a human by administering to the human a sufficient amount of phyto-oestrogen.
- the phyto-oestrogen is administered regularly on a daily basis over a sufficient period such as at least a month.
- the health conditions which may be prevented or ameliorated include cancer of the breast, cancer of the prostate, cancer of the uterus, cancer of the bowel, benign (or cystic) breast disease, pre ⁇ menstrual syndrome (also known as pre-menstrual tension), or adverse symptoms associated with menopause in women.
- the method and supplement in accordance with the invention also improves the health of a human having elevated levels of blood cholesterol.
- the product also is useful in avoiding or ameliorating cancer in persons. The symptoms produced by these conditions and the general well-being is also improved by the use of these supplements.
- the phyto-oestrogen in accordance with the invention may be obtained from a number of different sources.
- the phyto-oestrogens are extracted from a clover such as red clover or subterranean clover or from soya which contain high levels of phyto-oestrogens.
- a clover such as red clover or subterranean clover or from soya which contain high levels of phyto-oestrogens.
- any source rich in phyto-oestrogens may be used instead, if desired.
- isoflavones have been identified from these sources - they are principally genistein, biochanin A, daidzein, formononetin and glycitein. In plants these compounds occur principally in a glycoside form bound to sugars such as glucose, with smaller amounts present as the aglucone forms.
- the formulae of the isoflavones are:
- biochanin A is the same as for genistein but with a 4'-methoxy group, and similarly formononetin has the same structure as daidzein, but with a 4'-methoxy group.
- glycosidic isoflavones are hydrolysed to the aglucone form and biochanin A and formononetin are demethylated by bacterial fermentation to genistein and daidzein respectively.
- a small proportion of these free isoflavones are absorbed directly from the bowel and circulate in the blood.
- the bulk of the isoflavones remain in the bowel and undergo fermentation to form various metabolites which also are absorbed into the bloodstream.
- the principal metabolites which have been identified are equol and O- ⁇ fe.smethylangolensin.
- leguminous plants such as detailed here could be used as sources of phyto-oestrogens (principally isoflavones with lesser amounts of lignans and coumestans): Indian liquorice (Abrus precatorius); various species of Acacia spp. including, A. aneura, A. cibaria, A. longifolia, and A.
- oswcddi ⁇ ground nut (Apio t berosd, ground pea (Arachis hypogea); milk vetch (Astragalus edulis); marama bean (Bauhinia esculentd); sword bean (Cqfanus cajan indicus); jack bean (Canavalia ensiformis); sword bean (Canavalia gladiat ⁇ ); seaside sword bean (Canavalia rosed); various Cassia spp. including C. floribunda, C. laevigata, and C.
- Crotalcaia spp. including C. Iaburnifolia, and C.
- coccineus P. adenathus, P. angul ⁇ s, P. aureus, P. calcaratus, P. mungo, and P. polystachyus; garden pea (Pisum sativum); djenko bean (Pithecolobium lobatum); mesquite (various Prosopis spp.); goa bean (Psophocarpus scandens, P.
- tetragonolobus various Psoralea spp.; Sesbania bispinosa; yam bean (Sphenostylis stenocarpa); tamarind (T ⁇ m ⁇ rindus indica); fenugreek (Trigonell ⁇ foenum-gr ⁇ ecum); vetches (various Vivi ⁇ spp. including V. s ⁇ tiv ⁇ , V. atropurpurea, V. ervilia, and V. monantha); broad bean (Vicia faba); black grar ⁇ (Vigna mungo); various Vigna spp. including V. radiata, V. aconitifolia, V. adanatha, V. angularus, V. tribolata, V. umbelata, and V. unguiculata; and, earth pea (Voandzeia subterranea).
- the ideal sources of phyto-oestrogens for preparation of a supplement in accordance with the invention are preferably those which (i) are readily available, (ii) are relatively inexpensive, (iii) are readily and economically processed so as to yield the extract, (iv) have a high isoflavone content so as to provide high yields, and (v) have no known toxic components requiring selective removal or inactivation.
- red clover T. pratense
- subterranean clover T. subterranean
- soya flour has a level of 0J5-0.30 g%, lentils (0.08- 0J2 g%), chick peas (0.07-0J3 g%), and garden peas (0.02-0.03 g%).
- clovers contain approximately at least 10-30 times by weight the isoflavone content of other commonly available, human leguminous foodstuffs meaning that for manufacturing purposes, the yield of isoflavones per unit weight of plant material is many times greater from clover than from other legumes.
- Red clover and subterranean clover also are common fodder crops and are readily grown and are widely available. Clovers also are comparatively cheaper ($200/tonne) than crops such as soya and lentils ($500/tonne).
- Clovers With clovers, the isoflavones are recovered from the leaf rather than from the seed in the case of soya, beans, nuts and grams. This provides a substantially higher yield of isoflavones per unit area of pasture for clovers compared to other legumes because of the greater leaf matter compared to seed matter recovered per plant. Clovers also have an extended growing season, and faster growth rates compared to those legumes such as soya, lentils or chick peas where the seed is the end-product. Clover can be cropped for its leaf content repeatedly over a single growing season. An additional benefit of this is that as phyto-alexins, the isoflavone content increases in response to the stress of cropping.
- An additional feature of clovers is that there are wide varieties of cultivars with widely differing isoflavone levels and types. This allows blending of different cultivars to achieve the desired ratio of the different isoflavones, although it is equally possible to use a single cultivar which provides the desired ratio.
- soyabean flour may be used for enrichment of phyto-oestrogens but the substantially poorer (approx. 10%) yield of isoflavones compared to clovers means that the manufacturing costs are substantially greater and there is substantially greater amounts of waste products which requires disposal or further treatment for re-use as a foodstuff.
- the coumestrol content of soya is concentrated in the hull, and the daidzein content of soya is concentrated in the hypocotyl.
- the two cotyledons which comprise the bulk of the soyabean (90% by weight) contain the bulk of the genistein content of soya.
- the hulls being a fibrous component with little or no perceived nutritional value normally are separated and removed by physical means.
- the hypocotyls become separated following the splitting of the cotyledons, and while these currently generally are not deliberately isolated, they may be separated and isolated by passing the disturbed soyabeans over a sieve of sufficient pore size to selectively remove the small hypocotyl.
- the hypocotyl contains approx.
- the raw hypocotyl and hull material can be ground or milled to produce, for example, a dry powder or flour which then could be either blended or used separately as a dietary supplement in a variety of ways including, for example, as a powder, in a liquid form, in a granulated form, in a tablet or encapsulated form, or added to other prepared foodstuffs. Alternatively, it could be further processed to yield an enriched extract of phyto-oestrogens. Either or both of these materials also could be added to other leguminous material such as clover to provide the invention.
- the oestrogenic isoflavones are restricted principally to the leaf, fruit and root; the stem and petiole contain very little.
- the leaves are rarely regarded as foodstuff; indeed with these crops, the plants normally are allowed to die and dry out before the seed crop is harvested. Nevertheless, the fresh leaves of these crops could be regarded as a source of phyto-oestrogens for the invention although the much lower isoflavone content of the leaves of these crops compared to clovers, plus their generally slow growth compared to clovers, suggests that they would not be a preferred source of large-scale isoflavone enrichment.
- Clover grasses generally are not eaten by humans, except to a limited extent as sprouts of some of the pleasanter tasting varieties. Isoflavones are intensely astringent and are responsible in large part for the bitter taste of legumes.
- the invention also concerns formulations containing the phyto-oestrogens discussed above together with a dietary suitable excipient, diluent, carrier, or with a food.
- the formulation is in the form of a pill, tablet, capsule, or similar dosage form.
- the formulations may be a variety of kinds, such as nutritional supplements, pharmaceutical preparations, vitamin supplements, food additives or foods supplemented with the specified active phyto-oestrogens of the invention, liquid or solid preparations, including drinks, sterile injectable solutions, tablets, coated tablets, capsules, powders, drops, suspensions, or syrups, ointments, lotions, creams, pastes, gels, or the like.
- the formulations may be in convenient dosage forms, and may also include other active ingredients, and/or may contain conventional excipients, carriers and diluents.
- the inclusion of the subject phyto-oestrogens in herbal remedies and treatments is also a preferred part of the invention.
- the invention is also directed to the amelioration, prevention, or of various conditions responsive to treatment with the phyto-oestrogen substances of the invention.
- the preferred amounts to be administered to the human fall within 20 - 200 mg on a daily basis. More preferably the dosage is from 50 - 150 mg on a daily basis, and most preferably at a dosage of about 100 mg. If desired greater dosages can be administered for therapeutic reasons. In contrast to prior practices such high dosages were not possible. For example, dosages of up to or greater than 1000 mg may be suitable to treat some conditions.
- the treatment with the isoflavones should continue for a considerable period, ideally for at least a month, and ideally continuously for the whole period for which the health improvement advantages should accrue.
- the product according to the present invention yields a constant and accurately known amount of isoflavones.
- the product is also ideally a natural product, which has advantages for consumer acceptance, and in accordance with the supposed theory behind the invention may very possibly be one of the main causes for its beneficial effects.
- Whole legumes have a widely variable isoflavone content due to two main causes: the type of legume and the environmental effect.
- the type of legume typically has a wide range of isoflavone content.
- the miligram of isoflavone per hundred gram of whole foodstuff (dry weight) is given in the following table: Soya Products
- the product of the invention modulates the production and/or function of endogenous sex hormones in humans to modify or produce health improving effects, including the following: (i) lowered levels of various blood lipoproteins including, for instance, low-density and very-low-density cholesterol leading to reduced risk of development of atherosclerosis; (ii) reduced risk of development of cancer of the prostate; (iii) reduced risk of cancer of the 16 breast; (iv) reduced risk of development of cancer of the uterus; (v) reduced risk of development of cancer of the large bowel; (vi) reduced risk of development of the syndrome in women commonly referred to pre-menstrual syndrome (PMS), which includes pre-menstrual tension (PMT); (vii) reduced risk of development of many untoward symptoms (including dry vagina, peripheral flushing, depression etc) commonly associated in women with menopause; and for treating berrign breast disease
- PMS pre-menstrual syndrome
- PMT pre-menstrual tension
- the invention therefore is directed to a method for the prophylaxis or treatment of a human, to combat conditions associated with phyto-oestrogen deficiency, which comprises administering to the human an effective amount of phyto-oestrogen principally isoflavone but which might also include relatively smaller amounts of lignans and coumestans, ideally in a concentrated form, wherein the isoflavones include genistein, and/or biochanin A, and/or daidzein, and/or formononetin.
- Cancer of the breast generally is considered to be associated with oestrogenic dysfunction.
- Breast cancer cells may display more oestrogen receptors than normal breast cells and stimulation of these receptors by endogenous oestrogens is thought to be a prime source of stimulation of their malignant growth.
- synthetic anti-oestrogens are being used to prevent or treat the growth of malignant breast cells.
- Isoflavones are potent anti-oestrogens that could be expected to help prevent or to successfully treat breast cancer. It has been reported that the risk of breast cancer in western societies is indirectly proportional to the level of phyto-oestrogens in the diet and to the amounts of phyto-oestrogen metabolites excreted in the urine.
- Cancer of the prostate generally is considered to be associated with sex hormone dysfunction and the growth of prostatic cancer cells is influenced by oestrogens and androgens.
- the incidence of prostatic cancer is low in communities with high legume intake and, conversely, is high in Western socieites.
- Phyto-oestrogens are though to protect from development of prostatic cancer.
- One mechanism may be the effect of phyto-oestrogens on lowering the proportion of unbound:bound reproductive hormones in the blood.
- phyti-oestrogens particularly isoflavones, can have a direct influence on certain cellular enzymes within prostatic cells.
- Pre-menstrual syndrome has uncertain aetiology and pathogenesis, although most certainly is associated with reproductive hormone dysfunction, It also is a syndrome which has reportedly lower incidence in communities maintaining traditional high-legume diets. It is proposed that phyto-oestrogens will alleviate this condition by restoring balance to oestrogen metabolism.
- Menopausal syndrome is associated with changes in the oestrogen profile in the body with advancing age. Adverse clinical symptoms may be treated with oestrogen replacement therapy. There is evidence that foodstuffs high in phyto-oestrogens are a suitable alternative to synthetic hormones in this respect, producing alleviation of adverse clinical symptoms. Again, it is proposed that phyto-oestrogens will function by restoring balance to oestrogen metabolism.
- Benign (or cystic) breast disease has unknown aetiology. However, its association in women with certain stages of the menstrual cycle is strongly suggestive of oestrogen dysfunction. There currently is no successful treatment of this condition. Phyto-oestrogens are proposed to successfully treat this condition by restoring balance to oestrogen metabolism. Atherosclerosis is associated with cholesterol metabolism which in turn is associated closely with oestrogen metabolism. The generally higher incidence of atherosclerosis in young men versus young women, the rising incidence in women following menopause, and the lower incidence in post-menopausal women receiving oestrogen replacement therapy, all point to the moderating influence of oestrogens on cholesterol metabolism.
- a prime effect of oestrogens on cholesterol metabolism is stimulation of the liver to process cholesterol, particularly the highly atherogenic low-density lipoproteins and very low-density lipoproteins, into bile salts. It is proposed that phyto-oestrogens have an important hypocholesterolaemic effect in humans. There may be a variety of mechanisms involved, but one may be the stimulation by phyto- oestrogens of cholesterol catabolism by the liver.
- Tablets were prepared using red clover in accordance with the following procedure.
- the raw plant material is harvested and dried; such drying being either sun-drying or from applied heat.
- the dried product is then preferably chaffed, before the following extraction step, although this can be omitted if desired.
- the dried material is extracted in an aqueous: organic solvent mix.
- the aqueous phase is required to extract the water-soluble glycoside form of isoflavones, while the organic solvent is required to solubilise the water-insoluble aglycone form.
- the organic solvent can be either alcohol, chloroform, acetone or ethyl acetate.
- the ratio of solvent in the water can be between 0.1% and 99.9%.
- the preferred method is to use 60% alcohol in water.
- the isoflavones are extracted by exposing the plant material to the water: solvent mix.
- the exposure time in general terms is indirectly proportional to the temperature of the mixture.
- the temperature of the mix can range between ambient temperature and boiling temperature.
- the exposure time can be between 1 hour and 4 weeks or even longer. It has been determined that the adequate times for maximal recovery of isoflavones are 2 weeks at 50°C and 24 hours at 90 ⁇ C.
- the supernatant is separated from the undissolved plant material and the organic solvent removed by distillation. The aqueous supernatant then is concentrated, typically by distillation.
- Additional processing steps can be used, if desired, to convert the extracted natural product to capsule, tablet, or other convenient form for ingestion, using normal techniques for doing this. Otherwise the product can be packaged as a convenient food additive.
- Soyabeans were heated in dry air so that the hull became brittle.
- the beans then were processed through a tumble mill which removed the hull and split the bean the two cotyledons and the small-sized hypocotyl which separated from each other.
- the light-weight hulls then were removed by an air stream.
- the small-sized hypocotyls were separated from the larger -cotyledons by sieving through a steel wire mesh with apertures of 1 mm x 1 mm. This yielded approximately 87% purity of hypocotyls with 13% contamination by small cotyledon chips.
- EXAMPLE 3 effect of administering red clover extract to humans Seven normal individuals were studied for the comparative effects of red clover extract and whole legumes on blood cholesterol levels. All the individuals were consuming a standard Western diet with minimal levels of legumes.
- the red clover extract had a significantly (P ⁇ 0 .05) greater hypocholesterolaemic effect than did the whole beans.
- the effects on cholesterol levels are shown in the following table.
- the individuals are grouped according to their pre-treatment cholesterol levels (high, medium, low).
Abstract
Description
Claims
Priority Applications (15)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/602,191 USRE40792E1 (en) | 1992-05-19 | 1993-05-19 | Health supplements containing phyto-oestrogens, analogues or metabolites thereof |
AU40525/93A AU683838B2 (en) | 1992-05-19 | 1993-05-19 | Health supplements containing phyto-oestrogens, analogues or metabolites thereof |
CA002136233A CA2136233C (en) | 1992-05-19 | 1993-05-19 | Health supplements containing phyto-oestrogens, analogues or metabolites thereof |
EP93909679.8A EP0656786B2 (en) | 1992-05-19 | 1993-05-19 | Use of isoflavone phyto-oestrogen extracts of soy or clover |
US08/338,567 US5830887A (en) | 1992-05-19 | 1993-05-19 | Health supplements containing phyto-oestrogens, analogues or metabolites thereof |
BR9306393A BR9306393A (en) | 1992-05-19 | 1993-05-19 | Natural supplement and process to improve the health of a human being |
AT93909679T ATE275959T1 (en) | 1992-05-19 | 1993-05-19 | USE OF ISOFLAVONE PHYTO-ESTROGEN EXTRACTS OF SOY OR CLOVER |
JP5519718A JPH07506822A (en) | 1992-05-19 | 1993-05-19 | Health supplements containing phytoestrogens, analogs or their metabolites |
DK93909679T DK0656786T3 (en) | 1992-05-19 | 1993-05-19 | Use of isoflavone phytoestrogen extracts of soy or clover |
DE69333624T DE69333624T2 (en) | 1992-05-19 | 1993-05-19 | USE OF ISOFLAVON PHYTO-ESTROGEN EXTRACTS OF SOY OR CLOVER |
NO944435A NO944435D0 (en) | 1992-05-19 | 1994-11-18 | Health supplements containing phytoestrogens, analogs or metabolites thereof |
US10/611,151 US6987098B2 (en) | 1992-05-19 | 2003-07-02 | Health supplement |
US11/490,865 US20070179099A1 (en) | 1992-05-19 | 2006-07-20 | Methods of cholesterol reduction using isoflavones |
US13/078,696 US20120003337A1 (en) | 1992-05-19 | 2011-04-01 | Health supplements containing phyto-oestrogens, analogues or metabolites thereof |
US13/163,012 US20110305782A1 (en) | 1992-05-19 | 2011-06-17 | Methods of cholesterol reduction using isoflavones |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AUPL251192 | 1992-05-19 | ||
AUPL2511 | 1992-05-19 |
Related Child Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US08/338,567 A-371-Of-International US5830887A (en) | 1992-05-19 | 1993-05-19 | Health supplements containing phyto-oestrogens, analogues or metabolites thereof |
US33856795A Continuation | 1992-05-19 | 1995-01-12 | |
US08/910,837 Continuation US6562380B1 (en) | 1992-05-19 | 1997-08-13 | Methods for treating or reducing prediposition to breast cancer, pre-menstrual syndrome or symptoms associated with menopause by administration of phyto-estrogen |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1993023069A1 true WO1993023069A1 (en) | 1993-11-25 |
Family
ID=3776175
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/AU1993/000230 WO1993023069A1 (en) | 1992-05-19 | 1993-05-19 | Health supplements containing phyto-oestrogens, analogues or metabolites thereof |
Country Status (14)
Country | Link |
---|---|
US (12) | US5830887A (en) |
EP (2) | EP0656786B2 (en) |
JP (2) | JPH07506822A (en) |
AT (1) | ATE275959T1 (en) |
AU (1) | AU683838B2 (en) |
BR (1) | BR9306393A (en) |
CA (1) | CA2136233C (en) |
DE (1) | DE69333624T2 (en) |
DK (1) | DK0656786T3 (en) |
ES (1) | ES2225822T3 (en) |
NO (1) | NO944435D0 (en) |
NZ (1) | NZ252051A (en) |
PT (1) | PT656786E (en) |
WO (1) | WO1993023069A1 (en) |
Cited By (75)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0647408A1 (en) * | 1993-10-12 | 1995-04-12 | Protein Technologies International, Inc. | Protein isolate having an increased level of isoflavone compounds and process for producing the same |
EP0682877A1 (en) * | 1993-12-14 | 1995-11-22 | Nichimo Company Limited | Process for producing product from pulse and food containing product from pulse |
EP0693927A1 (en) * | 1993-04-16 | 1996-01-31 | Tufts University School Of Medicine | Method for treatment of menopausal and premenstrual symptoms |
US5506211A (en) * | 1994-05-09 | 1996-04-09 | The Uab Research Foundation | Genistein for use in inhibiting osteroclasts |
WO1996010341A1 (en) * | 1994-10-03 | 1996-04-11 | Schouten Industries B.V. | Food and health products |
US5587459A (en) * | 1994-08-19 | 1996-12-24 | Regents Of The University Of Minnesota | Immunoconjugates comprising tyrosine kinase inhibitors |
WO1998003084A1 (en) * | 1996-07-18 | 1998-01-29 | Nutricor, Inc. | Nutritious food preparations and methods for making them |
WO1998008503A1 (en) * | 1996-08-30 | 1998-03-05 | Novogen Research Pty. Ltd. | Therapeutic methods and compositions involving isoflavones |
EP0829261A3 (en) * | 1996-09-13 | 1998-04-01 | Director General of Shikoku National Agricultural Experiment Station, Ministry of Agriculture, Forestry and Fisheries | Composition comprising isoflavone or derivatives thereof for promoting fat-degradation in fat-cells |
WO1998042305A1 (en) * | 1997-03-26 | 1998-10-01 | Laboratoires Serobiologiques (Societe Anonyme) | Use of bambara nut seed extract(s) in a cosmetic composition |
WO1998048790A1 (en) * | 1997-04-28 | 1998-11-05 | Anticancer, Inc. | Use of genistein and related compounds to treat certain sex hormone related conditions |
WO1998050026A1 (en) * | 1997-05-01 | 1998-11-12 | Novogen Inc | Treatment or prevention of menopausal symptoms and osteoporosis |
US5855892A (en) * | 1997-09-19 | 1999-01-05 | Potter; Susan M. | Method for decreasing LDL-cholesterol concentration and increasing HDL-cholesterol concentration in the blood to reduce the risk of atherosclerosis and vascular disease |
WO1999006057A1 (en) * | 1997-07-30 | 1999-02-11 | Indena S.P.A. | Soya extract, process for its preparation and pharmaceutical composition |
DE19732866A1 (en) * | 1997-07-30 | 1999-02-18 | Indena Spa | Soya extract containing group B soya saponin(s) |
DE19732855A1 (en) * | 1997-07-30 | 1999-02-18 | Indena Spa | Soya extract containing group B soya saponin(s) |
WO1999007239A1 (en) * | 1997-07-25 | 1999-02-18 | Oy Borago Ab | Functional food preparate |
US5911995A (en) * | 1994-08-19 | 1999-06-15 | Regents Of The University Of Minnesota | EGF-genistein conjugates for the treatment of cancer |
EP0924986A1 (en) * | 1996-09-04 | 1999-06-30 | Biotics Research Corporation | Antioxidant derived from lentil and its preparation and uses |
US5919921A (en) * | 1996-06-11 | 1999-07-06 | Protein Technologies International, Inc. | Recovery of isoflavones from soy molasses |
EP0934060A1 (en) * | 1996-07-30 | 1999-08-11 | Energetics, Inc. | Dietary supplements |
WO1999043335A1 (en) * | 1998-02-25 | 1999-09-02 | Novogen Research Pty. Ltd. | Plant extracts and anti-cancer modalities involving the same |
US5952374A (en) * | 1997-09-29 | 1999-09-14 | Protein Technologies International, Inc. | Method for inhibiting the development of Alzheimer's disease and related dementias- and for preserving cognitive function |
WO1999049862A1 (en) * | 1998-03-30 | 1999-10-07 | The University Of Mississippi | Isoflavones for treating giardiasis and malaria |
US6004558A (en) * | 1998-02-25 | 1999-12-21 | Novogen, Inc. | Methods for treating cancer with legume plant extracts |
US6015785A (en) * | 1996-04-12 | 2000-01-18 | Protein Technologies International, Inc. | Aglucone isofavone enriched vegetable protein extract and isolate and process for producing |
WO2000003684A2 (en) * | 1998-07-16 | 2000-01-27 | Aaron Tabor | Soy formulations and their use for promoting health |
US6040333A (en) * | 1996-07-30 | 2000-03-21 | Energetics, Inc. | Dietary supplements |
WO2000016759A2 (en) * | 1998-09-17 | 2000-03-30 | Guido Schnyder | Genistein for the treatment of coronary heart disease and for the prevention of restenosis after percutaneous transluminal coronary angioplasty |
US6083553A (en) * | 1998-06-05 | 2000-07-04 | Protein Technologies International, Inc. | Recovery of isoflavones from soy molasses |
WO2000056177A2 (en) * | 1999-03-22 | 2000-09-28 | Stewart And Lynda Resnick Revocable Trust | Pomegranate extracts and methods of using thereof |
US6132795A (en) * | 1998-03-15 | 2000-10-17 | Protein Technologies International, Inc. | Vegetable protein composition containing an isoflavone depleted vegetable protein material with an isoflavone containing material |
WO2000064438A1 (en) * | 1999-04-28 | 2000-11-02 | Novogen Research Pty Ltd | Cardiovascular and bone treatment using isoflavones |
EP1049451A1 (en) * | 1997-12-24 | 2000-11-08 | Novogen Research Pty. Ltd. | Compositions and method for protecting skin from uv induced immunosuppression and skin damage |
US6146668A (en) * | 1997-04-28 | 2000-11-14 | Novogen, Inc. | Preparation of isoflavones from legumes |
WO2000071736A1 (en) * | 1999-05-20 | 2000-11-30 | The Samuel Roberts Noble Foundation, Inc. | Isoflavonoid methylation enzyme |
AU731951B2 (en) * | 1996-08-30 | 2001-04-05 | Novogen Research Pty Ltd | Therapeutic methods and compositions involving isoflavones |
US6261565B1 (en) | 1996-03-13 | 2001-07-17 | Archer Daniels Midland Company | Method of preparing and using isoflavones |
US6361807B1 (en) | 1999-04-19 | 2002-03-26 | Stewart And Lynda Resnick Revocable Trust | Pomegranate extracts and methods of using thereof |
US6391310B1 (en) | 1996-03-13 | 2002-05-21 | Archer Daniels Midland Company | Method of preparing and using isoflavones for the treatment of neurological symptoms |
WO2002055072A1 (en) * | 2001-01-16 | 2002-07-18 | Novogen Research Pty Ltd | Regulation of lipids and/or bone density and compositions therefor |
US6497906B1 (en) | 1992-05-19 | 2002-12-24 | Novogen Research Pty. Ltd. | Dietary supplements comprising soy hypocotyls containing at least one isoflavone |
US6500965B2 (en) | 2000-07-20 | 2002-12-31 | Linnea Sa | Dry extract which is rich in isoflavones in the form of aglycones and process for preparing the same |
US6509043B1 (en) | 1998-11-25 | 2003-01-21 | Nutri Pharma Asa | Composition comprising soy protein, dietary fibres and a phytoestrogen compound and use thereof in the prevention and/or treatment of pulmonary diseases |
US6521282B1 (en) | 1996-08-09 | 2003-02-18 | Protein Technologies International, Inc. | Aglucone isoflavone enriched vegetable flour and grit |
US6544566B1 (en) | 1999-04-23 | 2003-04-08 | Protein Technologies International, Inc. | Composition containing plant sterol, soy protein and isoflavone for reducing LDL cholesterol |
US6548072B1 (en) * | 1997-07-25 | 2003-04-15 | Chesebrough-Pond's Usa Co., Division Of Conopco, Inc. | Skin care compositions containing an organic extract of chick pea |
AU761047B2 (en) * | 1999-04-28 | 2003-05-29 | Novogen Research Pty Ltd | Cardiovascular and bone treatment using isoflavones |
US6579561B2 (en) | 1996-08-09 | 2003-06-17 | Protein Technologies International, Inc. | Aglucone isoflavone enriched vegetable flour and vegetable grit and process for making the same from a vegetable material containing isoflavone |
EP1321146A2 (en) * | 1998-03-11 | 2003-06-25 | Endorecherche Inc. | Inhibitors of type 5 and 3 17beta-hydroxysteroid dehydrogenase and methods for their use |
US6599536B1 (en) | 1998-03-26 | 2003-07-29 | Novogen Research Pty Ltd | Therapy of estrogen-associated disorders |
WO2003074064A1 (en) * | 2002-03-04 | 2003-09-12 | Medana Pharma Terpol Gorup S.A. | Solid composition containing isoflavonoids for oral administration and method of obtaining same |
US6630178B1 (en) | 1998-11-25 | 2003-10-07 | Nutri Pharma Asa | Composition comprising soy protein, dietary fibres and a phytoestrogen compound and use thereof in the prevention and/or treatment of cardiovascular diseases |
WO2004014886A1 (en) * | 2002-08-07 | 2004-02-19 | University Of Mississippi | Antigiardial agents and use thereof |
US6703051B1 (en) | 1998-10-13 | 2004-03-09 | Solae, Llc | Process for separating and recovering protein and isoflavones from a plant material |
EP1401260A2 (en) * | 2001-06-13 | 2004-03-31 | E.I. du Pont de Nemours and Company | A method for altering the isoflavonoid profile in the plant parts of an isoflavonoid-producing plant |
EP1438900A1 (en) * | 1998-07-16 | 2004-07-21 | Aaron Tabor | Use of soy formulations in food compositions |
AU779210B2 (en) * | 1997-05-01 | 2005-01-13 | Novogen Inc | Treatments or prevention of menopausal symptoms and osteoporosis |
US6878859B1 (en) | 1999-05-20 | 2005-04-12 | The Samuel Roberts Noble Foundation, Inc. | Isoflavonoid methylation enzyme |
US7045164B2 (en) | 2000-11-09 | 2006-05-16 | Cargill, Incorporated | Soybean processing |
WO2007073908A1 (en) | 2005-12-29 | 2007-07-05 | Evultis S.A. | A process for the isolation of pharmacologically active principles of vegetable and animal origin |
AU2004224982B2 (en) * | 1996-08-30 | 2007-09-13 | Novogen Research Pty Ltd | Therapeutic methods and compositions involving isoflavones |
US7285297B1 (en) | 1999-04-23 | 2007-10-23 | Archer-Daniels-Midland Company | Method of reducing low density liproprotein cholesterol concentration |
US7312344B2 (en) | 2001-03-08 | 2007-12-25 | Novogen Research Pty Limited | Dimeric isoflavones |
US7396855B2 (en) | 2002-07-24 | 2008-07-08 | Children's Hospital Medical Center | Compositions and products containing S-equol, and methods for their making |
US7488494B2 (en) | 1999-09-06 | 2009-02-10 | Novogen Research Pty Ltd. | Compositions and therapeutic methods involving isoflavones and analogues thereof |
AU2007201805B2 (en) * | 1996-08-30 | 2009-03-26 | Novogen Research Pty Ltd | Therapeutic methods and compositions involving isoflavones |
US7727563B2 (en) | 1999-04-19 | 2010-06-01 | Pom Wonderful, Llc | Methods of using pomegranate extracts for treating diabetes related atherosclerotic complications in humans |
WO2012004653A1 (en) * | 2010-07-07 | 2012-01-12 | Council Of Scientific & Industrial Research | Method for inhibition of nf-kb gene expression |
US8153684B2 (en) | 2002-10-29 | 2012-04-10 | Colorado State University Research Foundation | Use of equol for treating androgen mediated diseases |
US8221806B2 (en) | 1999-04-19 | 2012-07-17 | Stewart And Lynda Resnick Revocable Trust | Methods of using pomegranate extracts for causing regression in lesions due to arteriosclerosis in humans |
US8263140B1 (en) | 2008-04-16 | 2012-09-11 | Pom Wonderful, Llc | Pomegranate based skin protectant and topical application |
US8372454B2 (en) | 1999-04-19 | 2013-02-12 | Pom Wonderful Llc | Methods of making pomegranate compounds for the treatment of erectile dysfunction |
US8580846B2 (en) | 2002-10-29 | 2013-11-12 | Brigham Young University | Use of equol for ameliorating or preventing neuropsychiatric and neurodegenerative diseases or disorders |
US8668914B2 (en) | 2002-07-24 | 2014-03-11 | Brigham Young University | Use of equol for treating skin diseases |
Families Citing this family (109)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6007860A (en) * | 1994-09-02 | 1999-12-28 | Designing Health, Inc. | Preparing food supplement |
US6060101A (en) * | 1994-09-02 | 2000-05-09 | Designing Health, Inc. | Dietary food supplement |
US5656312A (en) * | 1994-09-02 | 1997-08-12 | Erasmus; Udo | Dietary food supplement and method of preparing |
US6060063A (en) * | 1996-12-31 | 2000-05-09 | Lansky; Ephraim Philip | Phytoestrogen supplements prepared from pomegranate material including pomegranate seeds |
US7005428B1 (en) | 1998-06-11 | 2006-02-28 | Endorecherche, Inc. | Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors |
JP2000119187A (en) * | 1998-10-15 | 2000-04-25 | Taisho Pharmaceut Co Ltd | Composition for preventing or improving depressive feeling |
ES2247858T3 (en) * | 1998-12-07 | 2006-03-01 | Ecosmart Technologies, Inc. | TREATMENT OF BREAST CANCER THROUGH THE USE OF ESSENTIAL PLANT OILS. |
WO2000050167A1 (en) * | 1999-02-24 | 2000-08-31 | Yandapalli Durga Prasad | A novel agropolymer used for purification of polluted water or contaminated water containing metal or ions and a method of producing the agropolymer |
US6413546B1 (en) | 1999-03-18 | 2002-07-02 | Indena, S.P.A. | Tablets incorporating isoflavone plant extracts and methods of manufacturing them |
JP2002542192A (en) | 1999-04-20 | 2002-12-10 | ボード オブ トラスティース, サザン イリノイ ユニバーシティ | How to treat clinical disease with isoflavones |
US20040072765A1 (en) * | 1999-04-28 | 2004-04-15 | Novogen Research Pty Ltd. | Cardiovascular and bone treatment using isoflavones |
EP1634601A3 (en) * | 1999-07-09 | 2008-02-13 | Sun Farm Corporation | Dietary supplement comprising soyabean, mushroom and mung bean |
US20090233999A1 (en) * | 1999-09-06 | 2009-09-17 | Novogen Research Pty Ltd | Compositions and therapeutic methods involving isoflavones and analogues thereof |
US6689387B1 (en) * | 1999-09-23 | 2004-02-10 | Bioresponse Llc | Phytochemicals for treatment of mastalgia and endometriosis |
US6534085B1 (en) * | 1999-09-23 | 2003-03-18 | Bioresponse L.L.C. | Phytochemicals for promoting weight loss |
US7384971B2 (en) | 1999-09-23 | 2008-06-10 | Bioresponse L.L.C. | Phytochemicals for the treatment of cervical dysplasia |
AUPQ520300A0 (en) * | 2000-01-21 | 2000-02-17 | Novogen Research Pty Ltd | Food product and process |
IL135335A (en) * | 2000-03-29 | 2013-12-31 | Lycored Natural Prod Ind Ltd | Use of carotenoids in the preparation of medicaments for preventing hormone induced adverse effects and pharmaceutical compositions comprising carotenoids |
WO2001074345A2 (en) * | 2000-03-31 | 2001-10-11 | Jonathan Ingram | Isoflavones for treatment of obesity |
US6989161B2 (en) * | 2000-06-12 | 2006-01-24 | Access Business Group International Llc | Phytonutrient nutritional supplement |
US7939115B2 (en) * | 2000-06-12 | 2011-05-10 | Access Business Group International Llc | Dietary supplement and related method |
US7438936B2 (en) * | 2000-06-12 | 2008-10-21 | Access Business Group International Llc | Dietary supplement and related method |
US7416749B2 (en) * | 2000-06-12 | 2008-08-26 | Access Business Group International Llc | Dietary supplement and related method |
US6511675B2 (en) | 2000-06-12 | 2003-01-28 | Access Business Group International, Llc | Composition and method for correcting a dietary phytochemical deficiency |
US20030054549A1 (en) * | 2000-07-18 | 2003-03-20 | Minoru Takebe | Stem cell reinforcing material |
US6552085B2 (en) * | 2000-08-16 | 2003-04-22 | Insmed Incorporated | Compositions containing hypoglycemically active stilbenoids |
US6410596B1 (en) * | 2000-08-16 | 2002-06-25 | Insmed Incorporated | Compositions containing hypoglycemically active stillbenoids |
US6326366B1 (en) * | 2000-08-22 | 2001-12-04 | Protein Technologies International | Hormone replacement therapy |
US7734724B2 (en) * | 2000-09-06 | 2010-06-08 | Xanboo Inc. | Automated upload of content based on captured event |
AU2000276898A1 (en) * | 2000-09-29 | 2002-04-22 | Jae-Seung Roh | Method for manufacturing green elemental bean sprouts using yellow light |
KR20020037140A (en) * | 2000-11-13 | 2002-05-18 | 권승룡 | An extract from Thermopsis alterniflora having hypolipidemic activity and pharmaceutical compositions thereof |
US20070059378A1 (en) * | 2001-02-02 | 2007-03-15 | Metagenics, Inc. | Medical composition for balancing bodily processes |
US20040220118A1 (en) * | 2001-02-02 | 2004-11-04 | Bland Jeffrey S. | Medical composition for balancing bodily processes |
US20060034954A1 (en) * | 2001-02-02 | 2006-02-16 | Bland Jeffrey S | Medical composition for balancing bodily processes |
US20030190381A1 (en) * | 2001-02-02 | 2003-10-09 | Bland Jeffrey S. | Medical composition for balancing bodily processes |
EP1358343A2 (en) * | 2001-02-09 | 2003-11-05 | Unilever N.V. | Process for the preparation of one or more statins by fermentation |
CN1373206A (en) * | 2001-02-28 | 2002-10-09 | 三照全盛特有限公司株式会社 | Leaven made from soybean germ, method for preparing same and sauces made therewith |
US20050119301A1 (en) * | 2001-03-16 | 2005-06-02 | Alan Husband | Treatment of restenosis |
US6787151B2 (en) | 2001-08-10 | 2004-09-07 | Lipton, Division Of Conopco, Inc. | Composition for lowering blood cholesterol |
US7338971B2 (en) * | 2001-08-30 | 2008-03-04 | El-Naggar Mawaheb M | Treatment of inflammatory, cancer, and thrombosis disorders |
US7348352B2 (en) * | 2001-10-23 | 2008-03-25 | Bioresponse L.L.C. | Diindolylmethane for the treatment of HPV infection |
AUPR846401A0 (en) * | 2001-10-25 | 2001-11-15 | Novogen Research Pty Ltd | 6-Hydroxy isoflavones, derivatives and medicaments involving same |
EP1310261A1 (en) * | 2001-11-09 | 2003-05-14 | Cognis France S.A. | Use of the extract of Vigna aconitifolia in a cosmetic and/or dermopharmaceutical composition |
WO2003077904A1 (en) * | 2002-03-15 | 2003-09-25 | Nichimo Co., Ltd. | Biological activity-promoting compositions containing soybean germ-origin isoflavone aglycon |
US7048960B2 (en) | 2002-03-22 | 2006-05-23 | Glenn Roy Pizzey | High lignan flaxseed product and product by process |
JP5219326B2 (en) * | 2002-04-18 | 2013-06-26 | モンサント テクノロジー エルエルシー | Oil body binding protein composition for reducing the risk of cardiovascular disease and method of use thereof |
US20050245492A1 (en) * | 2004-04-28 | 2005-11-03 | Lephart Edwin D | Use of equol for treating skin diseases |
US20060052440A1 (en) * | 2002-11-21 | 2006-03-09 | Nichimo Co., Ltd. | Medicinal composition for treating sudden deafness |
WO2004080474A1 (en) * | 2003-03-06 | 2004-09-23 | The Medical Research And Education Trust | Botanical extract compositions with anti-cancer or phytoestrogenic activity comprising prenyl flavonoids |
KR100868904B1 (en) * | 2003-03-27 | 2008-11-14 | (주)아모레퍼시픽 | A composition of skin external application containing the IB complex composing Soybean Germ Isoflavone Agylcone, Pomegranate Extract and Secoisolariciresinol for improving skin wrinkle and enhancing elasticity |
US20040228931A1 (en) * | 2003-05-12 | 2004-11-18 | Pharmachem Laboratories, Inc. | Novel composition for hormonal balance and uses thereof |
US7025998B2 (en) | 2003-05-30 | 2006-04-11 | Rotta Research Laboratorium S.P.A. | Phytoestrogens and probiotic for women's health |
EP1541040A1 (en) * | 2003-12-04 | 2005-06-15 | Cognis Iberia S.L | Composition for oral administration (VI) comprising an extract or active agents of Medicago sativa |
US20050152887A1 (en) * | 2004-01-14 | 2005-07-14 | Doctor's Signature Sales And Marketing International Corp. [Dba Life Force International | Protonic formulation |
JP2005229855A (en) * | 2004-02-18 | 2005-09-02 | Pola Chem Ind Inc | Food composition |
US20050220949A1 (en) * | 2004-03-31 | 2005-10-06 | Blas Arzubi | Highly bioefficient isoflavone-phospholipid molecular complexes and methods of making and using the same |
US8663679B2 (en) | 2004-04-29 | 2014-03-04 | Abbott Laboratories | Compositions for improving breast health in women |
US8080577B2 (en) * | 2004-05-06 | 2011-12-20 | Bioresponse, L.L.C. | Diindolylmethane formulations for the treatment of leiomyomas |
US8377484B1 (en) | 2004-05-06 | 2013-02-19 | Maria V. Tsiper | Tumor encapsulation for prevention and treatment of metastatic cancer disease |
EP1750732B1 (en) | 2004-05-10 | 2013-03-27 | Instituto Tecnologico y de Estudios Superiores de Monterrey | Cancer cell growth inhibition by black bean (phaseolus vulgaris l.) extracts |
US7727560B2 (en) * | 2004-05-18 | 2010-06-01 | Sou Yi Lu | Treating cancer, liver, kidney, platelet and hemopoietic disorder or complication |
US7433359B2 (en) * | 2004-05-28 | 2008-10-07 | Fujitsu Limited | Application of an Ethernet/MPLS half bridge to provide Ethernet multiplexing functions (EMF) in SONET network elements (NEs) |
ITMI20041342A1 (en) | 2004-07-05 | 2004-10-05 | Marfarma Holding S P A | RED TRIGOFLIO EXTRACT ENRICHED IN EQUOLO FOR FERMENTATION |
US7435431B2 (en) * | 2004-07-28 | 2008-10-14 | Abbott Laboratories | Method for controlling body weight in estrogen-insufficient women |
US7601370B2 (en) * | 2004-07-28 | 2009-10-13 | Abbott Laboratories | Method for controlling body weight in estrogen-insufficient women |
MX2007001128A (en) * | 2004-07-28 | 2007-04-17 | Abbott Lab | Nutritional compositions and methods for treating or preventing osteoporosis. |
CN101031292A (en) * | 2004-09-30 | 2007-09-05 | 不二制油株式会社 | Composition inhibiting sex hormone-binding globulin |
US20150005360A1 (en) | 2004-10-25 | 2015-01-01 | Nse Products, Inc. | Phytoestrogen compositions and associated methods |
JP4723849B2 (en) * | 2004-11-17 | 2011-07-13 | 株式会社ファンケル | Oral composition containing difructose anhydride |
WO2006083458A2 (en) | 2004-12-30 | 2006-08-10 | Bioresponse Llc | Use of diindolylmethane-related indoles for the treatment and prevention of respiratory syncytial virus associates conditions |
AU2005323934A1 (en) * | 2005-01-10 | 2006-07-13 | Hormos Medical Ltd | The use of a lignan for the manufacture of a composition for preventing or alleviating of symptoms relating to estrogen deficiency |
JP2006193459A (en) * | 2005-01-12 | 2006-07-27 | Fancl Corp | Oral composition for lowering blood cholesterol |
ATE480233T1 (en) * | 2005-02-15 | 2010-09-15 | Dsm Ip Assets Bv | COMPOSITIONS CONTAINING POLYSACCHARIDES |
US7595078B2 (en) | 2005-03-15 | 2009-09-29 | Glanbia Nutritionals Ireland Limited | Methods of increasing flaxseed hull recovery and resultant flax products |
US7563464B1 (en) | 2005-04-22 | 2009-07-21 | Bruce Eric Hudkins | Treatment of mucosal membranes utilizing phytoestrogen |
US20060280840A1 (en) * | 2005-05-24 | 2006-12-14 | Robertson Marion G | Universal protein formulation meeting multiple dietary needs for optimal health and enhancing the human immune system |
US8202546B2 (en) | 2005-08-04 | 2012-06-19 | Vertical Pharmaceuticals, Inc. | Nutritional supplement for use under physiologically stressful conditions |
US7901710B2 (en) | 2005-08-04 | 2011-03-08 | Vertical Pharmaceuticals, Inc. | Nutritional supplement for use under physiologically stressful conditions |
US8263137B2 (en) | 2005-08-04 | 2012-09-11 | Vertical Pharmaceuticals, Inc. | Nutritional supplement for women |
US7998500B2 (en) | 2005-08-04 | 2011-08-16 | Vertical Pharmaceuticals, Inc. | Nutritional supplement for women |
JP5030790B2 (en) * | 2005-12-06 | 2012-09-19 | 大塚製薬株式会社 | Equol-containing fermented soybean hypocotyl and method for producing the same |
US20070203227A1 (en) * | 2006-02-24 | 2007-08-30 | Herman Adlercreutz | Isoflavan and isoflavene compounds and their use as angiogenesis inhibitors |
EP1842541A1 (en) * | 2006-03-29 | 2007-10-10 | G.I.M.-Gesellschaft Für Innovative Medizin Gmbh Nfg Ohg | Plant components and extracts and uses thereof |
WO2007118245A2 (en) | 2006-04-07 | 2007-10-18 | The Board Of Regents Of The University Of Texas System | Methods and compositions related to adenoassociated virus-phage particles |
US8680140B2 (en) * | 2006-08-02 | 2014-03-25 | University Of Southern California | Phytoestrogenic formulations for alleviation or prevention of menopausal symptoms |
US20080108696A1 (en) | 2006-08-02 | 2008-05-08 | Brinton Roberta D | Phytoestrogenic Formulations for Alleviation or Prevention of Neurodegenerative Diseases |
WO2008039482A2 (en) * | 2006-09-26 | 2008-04-03 | The Regents Of The University Of California | Methods and compositions for cancer prevention and treatment |
US9517240B2 (en) | 2006-09-26 | 2016-12-13 | The Regents Of The University Of California | Methods and compositions for cancer prevention and treatment |
WO2008057253A2 (en) * | 2006-10-27 | 2008-05-15 | Bioresponse, L.L.C. | Anti-parasitic methods and compositions utilizing diindolylmethane-related indoles |
WO2008100560A2 (en) * | 2007-02-14 | 2008-08-21 | University Of Southern California | Estrogen receptor modulators, associated pharmaceutical compositions and methods of use |
US20090054517A1 (en) * | 2007-04-20 | 2009-02-26 | Lubahn Dennis B | Phytoestrogens As Regulators Of Hedgehog Signaling And Methods Of Their Use In Cancer Treatment |
AU2013203101B2 (en) * | 2007-06-13 | 2015-07-09 | Otsuka Pharmaceutical Co., Ltd. | Equol-containing extract, method for production thereof, method for extraction of equol, and equol-containing food |
AU2008262870B2 (en) | 2007-06-13 | 2013-07-11 | Otsuka Pharmaceutical Co., Ltd. | Equol-containing extract, method for production thereof, method for extraction of equol, and equol-containing food |
US8221803B1 (en) | 2007-06-25 | 2012-07-17 | OncoNatural Solutions, Inc. | Composition for prostate health |
US7867524B2 (en) * | 2007-10-05 | 2011-01-11 | David Rowland | Energizing formulation |
US20090176871A1 (en) * | 2008-01-07 | 2009-07-09 | Schoenwetter Phillip E | Treatments for Domestic Animals Having Sex Hormone Deficiencies Using Soy Germ Isoflavones |
US20110091435A1 (en) * | 2008-10-24 | 2011-04-21 | University Of Southern California | Phytoestrogenic formulations for alleviation or prevention of hair loss |
CA2746652C (en) * | 2008-12-11 | 2018-03-06 | Axcentua Pharmaceuticals Ab | Crystalline forms of genistein |
US7863325B2 (en) * | 2008-12-11 | 2011-01-04 | Axcentua Pharmaceuticals Ab | Crystalline genistein sodium salt dihydrate |
US20150290271A1 (en) * | 2010-07-12 | 2015-10-15 | Frutarom Switzerland Ltd. | Nutraceutical Composition Obtained from Fungus-Challenged Soy Seedlings |
JP6051436B2 (en) * | 2011-12-07 | 2016-12-27 | 国立研究開発法人産業技術総合研究所 | Estrogen-like active composition from red clover and flax seeds |
CA2909349C (en) | 2013-04-12 | 2023-01-03 | Rebecca Lambert Bent | Use of a multi-agent composition for treatment of cancer |
KR20170043245A (en) * | 2015-10-13 | 2017-04-21 | 숙명여자대학교산학협력단 | Pharmaceutical compositions for prevention and treatment of cancer and menopausal symptom of women containing Cajanus cajan (L.) Huth or its isolated compound as an active ingredient |
CN109071482A (en) * | 2016-01-15 | 2018-12-21 | 汉堡大学 | Carry the flavonoids type compound of O- rhamnopyranosyl residue |
US10039765B1 (en) | 2016-02-26 | 2018-08-07 | Michelle Ann Toothman | Vitamin supplement compositions with enhanced bioavailability |
US10617700B1 (en) | 2016-02-26 | 2020-04-14 | Michelle Ann Toothman | Vitamin supplement compositions with enhanced bioavailability |
TWI774660B (en) * | 2016-03-08 | 2022-08-21 | 日商大塚製藥股份有限公司 | Improving agent for physical and/or mental discomfort specific to female |
US20210401918A1 (en) * | 2018-11-23 | 2021-12-30 | Naturetech Co. Ltd. | Composition comprising combination of red clover extract and hops extract for improvement of menopausal disorder |
IT201900000343A1 (en) | 2019-01-10 | 2020-07-10 | Herbal E Antioxidant Derivatives S R L Ed In Forma Abbreviata H&Ad S R L | COMPOSITIONS FOR THE TREATMENT OF MENOPAUSE, OSTEOPENIA AND OSTEOPOROSIS, METABOLIC AND VASCULAR DISORDERS RELATED TO CLIMATER |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1482238A (en) * | 1974-05-03 | 1977-08-10 | Chinoin Gyogyszer Es Vegyeszet | Isoflavone derivatives |
EP0129667A1 (en) * | 1983-04-26 | 1985-01-02 | Takeda Chemical Industries, Ltd. | Compounds and pharmaceutical compositions for treatment of hypoovarianism |
EP0135172A2 (en) * | 1983-08-24 | 1985-03-27 | Takeda Chemical Industries, Ltd. | Method for treatment of osteoporosis |
EP0136569A2 (en) * | 1983-09-05 | 1985-04-10 | Takeda Chemical Industries, Ltd. | Isoflavone derivatives, their production and use |
Family Cites Families (99)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US35074A (en) * | 1862-04-29 | Improvement bn snow-plows for railroads | ||
DE1518002C3 (en) | 1965-01-02 | 1975-01-23 | Merck Patent Gmbh, 6100 Darmstadt | Isoflavans and isoflavens and processes for their production and medicinal products containing them |
DE1543749A1 (en) | 1966-02-16 | 1969-12-11 | Merck Ag E | Process for the preparation of 3,4-cis-4-aryl-isoflavans |
DK140447B (en) | 1970-10-06 | 1979-08-27 | Risoe Forsoegsanlaeg | Apparatus for mapping the cross-sectional dimensions of tubular workpieces. |
JPS54734B2 (en) | 1973-05-14 | 1979-01-16 | ||
US3973608A (en) | 1973-08-01 | 1976-08-10 | Zaidan Hojin Biseibutsu Kagaku Kenkyu Kai | Microbial production of certain isoflavones |
JPS576427B2 (en) | 1974-01-25 | 1982-02-04 | ||
JPS50160483A (en) | 1974-06-19 | 1975-12-25 | ||
GB1495189A (en) | 1975-09-12 | 1977-12-14 | Pfizer Ltd | 4-oxo-4h-benzopyran derivatives and process for their preparation |
DE2643800C2 (en) | 1976-09-29 | 1986-10-30 | Fritz Werner Industrie-Ausrüstungen GmbH, 6222 Geisenheim | Process for the production of xylose by the enzymatic hydrolysis of xylans |
US4157984A (en) | 1977-06-08 | 1979-06-12 | Z-L Limited | Antioxidants, antioxidant compositions and methods of preparing and using same |
US4264509A (en) | 1977-06-08 | 1981-04-28 | Z-L Limited Partnership | Isoflavones and related compounds, methods of preparing and using and antioxidant compositions containing same |
US4232122A (en) | 1979-01-17 | 1980-11-04 | Z-L Limited Partnership | Antioxidants, antioxidant compositions and methods of preparing and using same |
SU907060A1 (en) | 1979-02-07 | 1982-02-23 | Всесоюзный Научно-Исследовательский Биотехнический Институт | Process for preparing rose oil |
US4366082A (en) * | 1979-04-11 | 1982-12-28 | Z-L Limited Partnership | Isoflavones and related compounds, methods of preparing and using and antioxidant compositions containing same |
US4390559A (en) | 1979-04-11 | 1983-06-28 | Z-L Limited Partnership | Isoflavones and related compounds, methods of preparing and using and antioxidant compositions containing same |
US4379177A (en) * | 1979-07-05 | 1983-04-05 | The Procter & Gamble Company | Stable dehydrated cocrystalline amino acid food additives |
JPS5933232A (en) | 1982-08-19 | 1984-02-23 | Tokiwa Kanpou Seiyaku:Kk | Separation of saponin and flavone from leguminous plant |
US4935450A (en) * | 1982-09-17 | 1990-06-19 | Therapeutical Systems Corporation | Cancer therapy system for effecting oncolysis of malignant neoplasms |
US4557927A (en) | 1983-03-10 | 1985-12-10 | Kabushiki Kaisha Hoyashibara | Food products and process for producing same |
JPS61106016A (en) | 1984-10-27 | 1986-05-24 | 三菱電機株式会社 | Gas insulated bus |
DE3604575A1 (en) † | 1985-02-23 | 1986-08-28 | Degussa Ag, 6000 Frankfurt | Combination of flupirtine and spasmolytics with anticholinergic activity |
JPS61246124A (en) * | 1985-04-24 | 1986-11-01 | Yamanouchi Pharmaceut Co Ltd | Carcinostatic agent |
JPS61247396A (en) | 1985-04-24 | 1986-11-04 | Yamanouchi Pharmaceut Co Ltd | Production of genisteine |
JPS62106017A (en) | 1985-11-01 | 1987-05-16 | Yamanouchi Pharmaceut Co Ltd | Anti-tumor agent |
JPS62106016A (en) * | 1985-11-01 | 1987-05-16 | Yamanouchi Pharmaceut Co Ltd | Immuno-suppressor |
JPS62126286A (en) | 1985-11-25 | 1987-06-08 | Honda Motor Co Ltd | Vane structure of vane type rotary compressor |
JPS62126186A (en) | 1985-11-28 | 1987-06-08 | Tsumura Juntendo Inc | Production of isoflavone derivative |
GB8626344D0 (en) | 1986-11-04 | 1986-12-03 | Zyma Sa | Bicyclic compounds |
JPS6442427A (en) | 1987-08-10 | 1989-02-14 | Tsumura & Co | Sialidase inhibitor |
US4900693A (en) | 1987-12-21 | 1990-02-13 | United Technologies | Process for making polysilicon field plate with improved suppression of parasitic transistors |
JPH0832632B2 (en) | 1988-03-08 | 1996-03-29 | 株式会社太田胃散 | Urea nitrogen metabolism improver |
JPH0714927B2 (en) | 1988-04-06 | 1995-02-22 | キッコーマン株式会社 | Method for producing isoflavone compound |
JPH0267218A (en) * | 1988-08-31 | 1990-03-07 | Nagakura Seiyaku Kk | Virus genome inactivator |
JPH0269165A (en) | 1988-09-02 | 1990-03-08 | Mitsugi Ohashi | Cancer suppressing food |
JPH02124883A (en) | 1988-11-04 | 1990-05-14 | Kitasato Inst:The | Isoflavone derivative having antioxidation activity and production thereof |
JP2753719B2 (en) * | 1988-12-15 | 1998-05-20 | 日本油脂株式会社 | Manufacturing method of liposome preparation |
JPH0347049A (en) | 1989-03-09 | 1991-02-28 | Sanyu:Kk | Food material from waste solution 'yu' of bean-curd and preparation of health drink |
US5153230A (en) | 1989-10-06 | 1992-10-06 | Perfective Cosmetics, Inc. | Topical skin cream composition |
CH679584A5 (en) * | 1989-11-10 | 1992-03-13 | Nestle Sa | |
KR0149172B1 (en) | 1990-04-06 | 1998-10-15 | 기율라스주크, 타마스스주츠 | An improved process for the preparation of substituted isoflavone derivatives |
US5204369A (en) * | 1991-07-01 | 1993-04-20 | The Endowment For Research In Human Biology | Method for the inhibition of aldh-i useful in the treatment of alcohol dependence or alcohol abuse |
GB2261671B (en) | 1991-11-16 | 1996-07-03 | Gb Biotech | Gel production from plant matter |
JPH05170756A (en) | 1991-12-20 | 1993-07-09 | Kikkoman Corp | Production of isoflavone compound |
CA2136233C (en) | 1992-05-19 | 2004-03-30 | Graham Edmund Kelly | Health supplements containing phyto-oestrogens, analogues or metabolites thereof |
JPH0640876A (en) | 1992-07-23 | 1994-02-15 | Kobe Steel Ltd | External preparation for shielding human health from adverse effect due to ultraviolet light |
JPH0686682A (en) | 1992-07-23 | 1994-03-29 | Kobe Steel Ltd | Production of 4',7,8-trihydroxyisoflavone |
JPH0640909A (en) | 1992-07-23 | 1994-02-15 | Kobe Steel Ltd | Superoxide-dismutase-like activation agent |
US5301251A (en) * | 1992-12-15 | 1994-04-05 | Alcatel Network Systems, Inc. | Method and apparatus for affixing an optic fiber tip in position with respect to a fiber communications circuit |
EP0693927A4 (en) | 1993-04-16 | 1997-05-28 | Univ Tufts Med | Method for treatment of menopausal and premenstrual symptoms |
JPH06321752A (en) | 1993-05-07 | 1994-11-22 | Kao Corp | Skin beautifying agent |
US5320949A (en) * | 1993-10-12 | 1994-06-14 | Protein Technologies International, Inc. | Process for producing aglucone isoflavone enriched vegetable protein fiber |
EP0723536B2 (en) | 1993-10-12 | 2006-06-14 | Archer Daniels Midland Company | An aglucone isoflavone enriched vegetable protein whey, and process for producing |
RU2142957C1 (en) | 1993-10-12 | 1999-12-20 | Протеин Текнолоджиз Интернэшнл, Инк. | Method of preparing extract enriched with aglucone isoflavones |
US5885632A (en) | 1993-12-14 | 1999-03-23 | Nichimo Co., Ltd. | Process for preparing a product from a pulse crop as a starting material and a food containing the product prepared from a pulse crop as a starting material |
JP3078694B2 (en) | 1993-12-17 | 2000-08-21 | キッコーマン株式会社 | How to make genistein |
IL112061A (en) | 1994-01-13 | 1999-10-28 | Bristol Myers Squibb Co | Methods for the preparation of taxanes |
US6369103B1 (en) | 1994-01-18 | 2002-04-09 | Bristol-Myers Squibb Company | Method for preventing or reducing risk of onset of cardiovascular events employing an HMG CoA reductase inhibitor |
US5366082A (en) * | 1994-01-25 | 1994-11-22 | Haytayan Harry M | Nail support strips |
IL112639A0 (en) | 1994-03-11 | 1995-05-26 | Bristol Myers Squibb Co | A pharmaceutical composition containing pravastin |
US5506211A (en) | 1994-05-09 | 1996-04-09 | The Uab Research Foundation | Genistein for use in inhibiting osteroclasts |
US5424331A (en) * | 1994-06-10 | 1995-06-13 | Bio-Virus Research Incorporated | Pharmaceutical compositions and dietary soybean food products for the prevention of osteoporosis |
US5547866A (en) | 1994-07-20 | 1996-08-20 | The Regents Of The University Of California | Taxane production in haploid-derived cell cultures |
DE4432947C2 (en) | 1994-09-16 | 1998-04-09 | New Standard Gmbh | Agent for the treatment of the skin and its use |
AU3689095A (en) * | 1994-10-03 | 1996-04-26 | Schouten Industries B.V. | Food and health products |
US5516528A (en) | 1995-01-13 | 1996-05-14 | Wake Forest University | Dietary phytoestrogen in estrogen replacement therapy |
US5523087A (en) | 1995-02-15 | 1996-06-04 | Bio-Virus Research Incorporated | Pharmaceutical compositions for the treatment of diabetic male sexual dysfunction |
US5569459A (en) | 1995-02-15 | 1996-10-29 | Bio-Virus Research Incorporated | Pharmaceutical compositions for the management of premenstrual syndrome and alleviation of menopausal disorders |
US5679806A (en) | 1995-02-24 | 1997-10-21 | Hauser, Inc. | Process for the isolation and purification of isoflavones |
AUPN166195A0 (en) * | 1995-03-13 | 1995-04-06 | Norvet Research Pty Limited | Process for glucan extraction |
JPH08283283A (en) | 1995-04-14 | 1996-10-29 | Kikkoman Corp | Malonylisoflavone glucoside and method for obtaining isoflavone glucoside or isoflavone aglycon from the same substance |
US5639785A (en) | 1995-06-07 | 1997-06-17 | Global Pharma, Ltd. | Methods for the treatment of baldness and gray hair using isoflavonoid derivatives |
US5554519A (en) | 1995-08-07 | 1996-09-10 | Fermalogic, Inc. | Process of preparing genistein |
JPH0967362A (en) | 1995-09-01 | 1997-03-11 | Sankyo Co Ltd | 5alpha-reductase inhibitor, bisisoflavone |
US5702752A (en) | 1996-03-13 | 1997-12-30 | Archer Daniels Midland Company | Production of isoflavone enriched fractions from soy protein extracts |
US6261565B1 (en) * | 1996-03-13 | 2001-07-17 | Archer Daniels Midland Company | Method of preparing and using isoflavones |
US5821361A (en) | 1996-06-11 | 1998-10-13 | Protein Technologies International, Inc. | Recovery of isoflavones from soy molasses |
JPH1059956A (en) | 1996-08-22 | 1998-03-03 | Kikkoman Corp | New isoflavone derivative and its production |
AUPO203996A0 (en) | 1996-08-30 | 1996-09-26 | Novogen Research Pty Ltd | Therapeutic uses |
US5726034A (en) | 1996-09-06 | 1998-03-10 | Protein Technologies International, Inc. | Aglucone isoflavone enriched vegetable protein extract and protein material, and high genistein and daidzein content materials and process for producing the same |
US5804234A (en) | 1996-09-13 | 1998-09-08 | Suh; John D. | Plant protein for nutritional products and method of making same |
US5733926A (en) | 1996-12-13 | 1998-03-31 | Gorbach; Sherwood L. | Isoflavonoids for treatment and prevention of alzheimer dementia and reduced cognitive functions |
US6146668A (en) | 1997-04-28 | 2000-11-14 | Novogen, Inc. | Preparation of isoflavones from legumes |
EP0979074A4 (en) | 1997-05-01 | 2003-07-09 | Novogen Inc | Treatment or prevention of menopausal symptoms and osteoporosis |
US6060070A (en) | 1997-06-11 | 2000-05-09 | Gorbach; Sherwood L. | Isoflavonoids for treatment and prevention of aging skin and wrinkles |
US5855892A (en) | 1997-09-19 | 1999-01-05 | Potter; Susan M. | Method for decreasing LDL-cholesterol concentration and increasing HDL-cholesterol concentration in the blood to reduce the risk of atherosclerosis and vascular disease |
US5942539A (en) | 1997-10-03 | 1999-08-24 | Wake Forest University | Methods of treating or preventing endometriosis with phytoestrogens |
AUPP112497A0 (en) | 1997-12-24 | 1998-01-22 | Novogen Research Pty Ltd | Compositions and method for protecting skin from UV induced immunosupression and skin damage |
US6004558A (en) | 1998-02-25 | 1999-12-21 | Novogen, Inc. | Methods for treating cancer with legume plant extracts |
US6132795A (en) | 1998-03-15 | 2000-10-17 | Protein Technologies International, Inc. | Vegetable protein composition containing an isoflavone depleted vegetable protein material with an isoflavone containing material |
AU2904899A (en) | 1998-03-16 | 1999-10-11 | Procter & Gamble Company, The | Compositions for regulating skin appearance |
AUPP260798A0 (en) | 1998-03-26 | 1998-04-23 | Novogen Research Pty Ltd | Treatment of medical related conditions with isoflavone containing extracts of clover |
AUPP868599A0 (en) * | 1999-02-15 | 1999-03-11 | Novogen Research Pty Ltd | Production of isoflavone derivatives |
US6544566B1 (en) | 1999-04-23 | 2003-04-08 | Protein Technologies International, Inc. | Composition containing plant sterol, soy protein and isoflavone for reducing LDL cholesterol |
US20040072765A1 (en) | 1999-04-28 | 2004-04-15 | Novogen Research Pty Ltd. | Cardiovascular and bone treatment using isoflavones |
AUPQ266199A0 (en) | 1999-09-06 | 1999-09-30 | Novogen Research Pty Ltd | Compositions and therapeutic methods involving isoflavones and analogues thereof |
AUPQ520300A0 (en) | 2000-01-21 | 2000-02-17 | Novogen Research Pty Ltd | Food product and process |
AUPR255401A0 (en) | 2001-01-16 | 2001-02-08 | Novogen Research Pty Ltd | Regulation of lipids and/or bone density and compositions therefor |
AUPR363301A0 (en) | 2001-03-08 | 2001-04-05 | Novogen Research Pty Ltd | Dimeric isoflavones |
-
1993
- 1993-05-19 CA CA002136233A patent/CA2136233C/en not_active Expired - Lifetime
- 1993-05-19 DK DK93909679T patent/DK0656786T3/en active
- 1993-05-19 US US08/338,567 patent/US5830887A/en not_active Ceased
- 1993-05-19 JP JP5519718A patent/JPH07506822A/en active Pending
- 1993-05-19 AU AU40525/93A patent/AU683838B2/en not_active Withdrawn - After Issue
- 1993-05-19 DE DE69333624T patent/DE69333624T2/en not_active Expired - Lifetime
- 1993-05-19 NZ NZ252051A patent/NZ252051A/en unknown
- 1993-05-19 WO PCT/AU1993/000230 patent/WO1993023069A1/en active IP Right Grant
- 1993-05-19 BR BR9306393A patent/BR9306393A/en not_active Application Discontinuation
- 1993-05-19 AT AT93909679T patent/ATE275959T1/en active
- 1993-05-19 US US09/602,191 patent/USRE40792E1/en not_active Expired - Lifetime
- 1993-05-19 ES ES93909679T patent/ES2225822T3/en not_active Expired - Lifetime
- 1993-05-19 EP EP93909679.8A patent/EP0656786B2/en not_active Expired - Lifetime
- 1993-05-19 EP EP04103669A patent/EP1477178A3/en not_active Withdrawn
- 1993-05-19 PT PT93909679T patent/PT656786E/en unknown
-
1994
- 1994-11-18 NO NO944435A patent/NO944435D0/en not_active Application Discontinuation
-
1997
- 1997-08-13 US US08/910,837 patent/US6562380B1/en not_active Expired - Fee Related
-
1999
- 1999-10-19 US US09/421,069 patent/US6642212B1/en not_active Expired - Fee Related
-
2000
- 2000-04-11 US US09/547,100 patent/US6497906B1/en not_active Expired - Fee Related
-
2002
- 2002-10-21 US US10/274,371 patent/US7045155B2/en not_active Expired - Fee Related
-
2003
- 2003-02-07 JP JP2003031777A patent/JP2004002304A/en active Pending
- 2003-07-02 US US10/611,151 patent/US6987098B2/en not_active Expired - Fee Related
- 2003-07-02 US US10/611,087 patent/US20040048812A1/en not_active Abandoned
-
2004
- 2004-03-11 US US10/799,022 patent/US20040170713A1/en not_active Abandoned
-
2006
- 2006-07-20 US US11/490,865 patent/US20070179099A1/en not_active Abandoned
-
2011
- 2011-04-01 US US13/078,696 patent/US20120003337A1/en not_active Abandoned
- 2011-06-17 US US13/163,012 patent/US20110305782A1/en not_active Abandoned
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1482238A (en) * | 1974-05-03 | 1977-08-10 | Chinoin Gyogyszer Es Vegyeszet | Isoflavone derivatives |
EP0129667A1 (en) * | 1983-04-26 | 1985-01-02 | Takeda Chemical Industries, Ltd. | Compounds and pharmaceutical compositions for treatment of hypoovarianism |
EP0135172A2 (en) * | 1983-08-24 | 1985-03-27 | Takeda Chemical Industries, Ltd. | Method for treatment of osteoporosis |
EP0136569A2 (en) * | 1983-09-05 | 1985-04-10 | Takeda Chemical Industries, Ltd. | Isoflavone derivatives, their production and use |
Non-Patent Citations (4)
Title |
---|
CHEMICAL ABSTRACTS, Volume 115, No. 8, issued 26 August 1991 (26.08.91) (Columbus, Ohio) USA, LIU, Y. et al., "Effects of Solid Dispersion of Daidzein on the Blood Pressure of Spontaneously Hypertensive Rats", page 406, Abstract No. 78763p, Shenyang Yaoxueyuan Xuebao 1991, 8(2) 105-8 (Ch.), see entire Abstract. * |
PATENT ABSTRACTS OF JAPAN, C-452, page 118; & JP,A,62 106 016 (YAMANOUCHI PHARMACEUT CO. LTD) 16 May 1987 (16.05.87), see entire Abstract. * |
PATENT ABSTRACTS OF JAPAN, C-722, page 98; & JP,A,02 067 218 (NAGAKURA SEIYAKU K.K.) 7 March 1990 (07-03-90), see entire Abstract, particularly formula I. * |
PATENT ABSTRACTS OF JAPAN, C-757, page 17; & JP,A,02 160 722 (NIPPON OIL AND FATS CO LTD) 20 June 1990 (20.06.90), see entire Abstract. * |
Cited By (142)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6562380B1 (en) | 1992-05-19 | 2003-05-13 | Novogen Research Pty Limited | Methods for treating or reducing prediposition to breast cancer, pre-menstrual syndrome or symptoms associated with menopause by administration of phyto-estrogen |
US6642212B1 (en) | 1992-05-19 | 2003-11-04 | Novogen Research Pty. Ltd. | Health supplements containing phyto-oestrogens, analogues or metabolites thereof |
US6497906B1 (en) | 1992-05-19 | 2002-12-24 | Novogen Research Pty. Ltd. | Dietary supplements comprising soy hypocotyls containing at least one isoflavone |
EP0693927A4 (en) * | 1993-04-16 | 1997-05-28 | Univ Tufts Med | Method for treatment of menopausal and premenstrual symptoms |
EP0693927A1 (en) * | 1993-04-16 | 1996-01-31 | Tufts University School Of Medicine | Method for treatment of menopausal and premenstrual symptoms |
US5498631A (en) * | 1993-04-16 | 1996-03-12 | Tufts University School Of Medicine | Method for treatment of menopausal and premenstrual symptoms |
EP0647408A1 (en) * | 1993-10-12 | 1995-04-12 | Protein Technologies International, Inc. | Protein isolate having an increased level of isoflavone compounds and process for producing the same |
US5885632A (en) * | 1993-12-14 | 1999-03-23 | Nichimo Co., Ltd. | Process for preparing a product from a pulse crop as a starting material and a food containing the product prepared from a pulse crop as a starting material |
EP0682877A4 (en) * | 1993-12-14 | 1997-06-04 | Nichimo Kk | Process for producing product from pulse and food containing product from pulse. |
EP0682877A1 (en) * | 1993-12-14 | 1995-11-22 | Nichimo Company Limited | Process for producing product from pulse and food containing product from pulse |
US5506211A (en) * | 1994-05-09 | 1996-04-09 | The Uab Research Foundation | Genistein for use in inhibiting osteroclasts |
US5587459A (en) * | 1994-08-19 | 1996-12-24 | Regents Of The University Of Minnesota | Immunoconjugates comprising tyrosine kinase inhibitors |
US5911995A (en) * | 1994-08-19 | 1999-06-15 | Regents Of The University Of Minnesota | EGF-genistein conjugates for the treatment of cancer |
WO1996010341A1 (en) * | 1994-10-03 | 1996-04-11 | Schouten Industries B.V. | Food and health products |
US6518319B1 (en) | 1996-03-13 | 2003-02-11 | Archer Daniels Midland Company | Method of preparing and using compositions extracted from vegetable matter for the treatment of female symptoms |
US6509381B2 (en) | 1996-03-13 | 2003-01-21 | Archer Daniels Midland Company | Method of preparing and using compositions extracted from vegetable matter for the treatment of neurological conditions |
US6399072B1 (en) | 1996-03-13 | 2002-06-04 | Archer Daniels Midland Company | Method of preparing and using isoflavones for the treatment of alcoholism |
US6395279B1 (en) | 1996-03-13 | 2002-05-28 | Archer Daniels Midland Company | Method of preparing and using isoflavones for the treatment of cancer |
US6391309B1 (en) | 1996-03-13 | 2002-05-21 | Archer Daniesl Midland Company | Method of preparing and using isoflavones for the treatment of female symptoms |
US6391310B1 (en) | 1996-03-13 | 2002-05-21 | Archer Daniels Midland Company | Method of preparing and using isoflavones for the treatment of neurological symptoms |
US6391308B1 (en) | 1996-03-13 | 2002-05-21 | Archer Daniels Midland Company | Method of preparing and using isoflavones for the treatment of blood related illnesses |
US6900240B2 (en) | 1996-03-13 | 2005-05-31 | Archer-Daniels-Midland Company | Method of preparing and using compositions extracted from vegetable matter for the treatment of cancer |
US6261565B1 (en) | 1996-03-13 | 2001-07-17 | Archer Daniels Midland Company | Method of preparing and using isoflavones |
US6015785A (en) * | 1996-04-12 | 2000-01-18 | Protein Technologies International, Inc. | Aglucone isofavone enriched vegetable protein extract and isolate and process for producing |
US6495141B2 (en) | 1996-06-11 | 2002-12-17 | Protein Technologies International, Inc. | Recovery of isoflavones from soy molasses |
US6706292B2 (en) | 1996-06-11 | 2004-03-16 | Solae, Llc | Recovery of isoflavones from soy molasses |
US5919921A (en) * | 1996-06-11 | 1999-07-06 | Protein Technologies International, Inc. | Recovery of isoflavones from soy molasses |
US6323018B1 (en) | 1996-06-11 | 2001-11-27 | Protein Technologies Int'l Lnc. | Recovery of isoflavones from soy molasses |
US6664382B2 (en) | 1996-06-11 | 2003-12-16 | Solae, Llc | Recovery of isoflavones from soy molasses |
US5990291A (en) * | 1996-06-11 | 1999-11-23 | Protein Technologies International, Inc. | Recovery of isoflavones from soy molasses |
WO1998003084A1 (en) * | 1996-07-18 | 1998-01-29 | Nutricor, Inc. | Nutritious food preparations and methods for making them |
EP0934060A4 (en) * | 1996-07-30 | 2001-01-03 | Energetics | Dietary supplements |
EP0934060A1 (en) * | 1996-07-30 | 1999-08-11 | Energetics, Inc. | Dietary supplements |
US6040333A (en) * | 1996-07-30 | 2000-03-21 | Energetics, Inc. | Dietary supplements |
US6521282B1 (en) | 1996-08-09 | 2003-02-18 | Protein Technologies International, Inc. | Aglucone isoflavone enriched vegetable flour and grit |
US6579561B2 (en) | 1996-08-09 | 2003-06-17 | Protein Technologies International, Inc. | Aglucone isoflavone enriched vegetable flour and vegetable grit and process for making the same from a vegetable material containing isoflavone |
CN101007000B (en) * | 1996-08-30 | 2011-12-28 | 诺沃根研究有限公司 | Therapeutic methods and compositions involving isoflavones |
EP1927352A2 (en) * | 1996-08-30 | 2008-06-04 | Novogen Research Pty. Ltd. | Therapeutic methods and compositions involving isoflavones |
AU731951B2 (en) * | 1996-08-30 | 2001-04-05 | Novogen Research Pty Ltd | Therapeutic methods and compositions involving isoflavones |
US7915308B2 (en) | 1996-08-30 | 2011-03-29 | Novogen Research Pty Ltd | Therapeutic methods and compositions involving isoflavones |
AU2007201805B2 (en) * | 1996-08-30 | 2009-03-26 | Novogen Research Pty Ltd | Therapeutic methods and compositions involving isoflavones |
EP1927352A3 (en) * | 1996-08-30 | 2008-11-19 | Novogen Research Pty. Ltd. | Therapeutic methods and compositions involving isoflavones |
US7419998B2 (en) * | 1996-08-30 | 2008-09-02 | Novogen Research Pty Ltd | Therapeutic methods and compositions involving isoflavones |
US6649648B1 (en) | 1996-08-30 | 2003-11-18 | Novogen Research Pty Limited | Therapeutic methods and compositions involving isoflavones |
AU2004224982B2 (en) * | 1996-08-30 | 2007-09-13 | Novogen Research Pty Ltd | Therapeutic methods and compositions involving isoflavones |
US7202273B2 (en) | 1996-08-30 | 2007-04-10 | Novogen Research Pty Ltd | Therapeutic methods and compositions involving isoflavones |
WO1998008503A1 (en) * | 1996-08-30 | 1998-03-05 | Novogen Research Pty. Ltd. | Therapeutic methods and compositions involving isoflavones |
GB2331015B (en) * | 1996-08-30 | 2001-05-09 | Novogen Res Pty Ltd | Therapeutic methods and compositions involving isoflavones |
CN1301710C (en) * | 1996-08-30 | 2007-02-28 | 诺沃根研究有限公司 | Therapeutic methods and compositions involving isoflavones |
GB2331015A (en) * | 1996-08-30 | 1999-05-12 | Novogen Res Pty Ltd | Therapeutic methods and compositions involving isoflavones |
EP0924986A4 (en) * | 1996-09-04 | 2002-11-27 | Biotics Res Corp | Antioxidant derived from lentil and its preparation and uses |
EP0924986A1 (en) * | 1996-09-04 | 1999-06-30 | Biotics Research Corporation | Antioxidant derived from lentil and its preparation and uses |
EP0829261A3 (en) * | 1996-09-13 | 1998-04-01 | Director General of Shikoku National Agricultural Experiment Station, Ministry of Agriculture, Forestry and Fisheries | Composition comprising isoflavone or derivatives thereof for promoting fat-degradation in fat-cells |
US6391320B1 (en) | 1997-03-26 | 2002-05-21 | Laboratoires Serobiologiques (Societe Anonyme) | Cosmetic composition containing an extract from the seed of bambara (Voandzeia subterranea) nut |
FR2761264A1 (en) * | 1997-03-26 | 1998-10-02 | Serobiologiques Lab Sa | USE OF BAMBARA PEA SEED EXTRACT (S) IN A COSMETIC COMPOSITION AND CORRESPONDING COSMETIC COMPOSITION |
WO1998042305A1 (en) * | 1997-03-26 | 1998-10-01 | Laboratoires Serobiologiques (Societe Anonyme) | Use of bambara nut seed extract(s) in a cosmetic composition |
US6146668A (en) * | 1997-04-28 | 2000-11-14 | Novogen, Inc. | Preparation of isoflavones from legumes |
WO1998048790A1 (en) * | 1997-04-28 | 1998-11-05 | Anticancer, Inc. | Use of genistein and related compounds to treat certain sex hormone related conditions |
US7033621B1 (en) | 1997-04-28 | 2006-04-25 | Novogen, Inc. | Isoflavone compositions produced from legumes |
US6340703B1 (en) | 1997-05-01 | 2002-01-22 | Novogen, Inc. | Treatment or prevention of osteoporosis |
WO1998050026A1 (en) * | 1997-05-01 | 1998-11-12 | Novogen Inc | Treatment or prevention of menopausal symptoms and osteoporosis |
US20110312906A1 (en) * | 1997-05-01 | 2011-12-22 | Novogen, Inc. | Treatment or reduction of menopausal symptoms |
AU779210B2 (en) * | 1997-05-01 | 2005-01-13 | Novogen Inc | Treatments or prevention of menopausal symptoms and osteoporosis |
US6548072B1 (en) * | 1997-07-25 | 2003-04-15 | Chesebrough-Pond's Usa Co., Division Of Conopco, Inc. | Skin care compositions containing an organic extract of chick pea |
WO1999007239A1 (en) * | 1997-07-25 | 1999-02-18 | Oy Borago Ab | Functional food preparate |
DE19732866A1 (en) * | 1997-07-30 | 1999-02-18 | Indena Spa | Soya extract containing group B soya saponin(s) |
WO1999006057A1 (en) * | 1997-07-30 | 1999-02-11 | Indena S.P.A. | Soya extract, process for its preparation and pharmaceutical composition |
US7108871B2 (en) | 1997-07-30 | 2006-09-19 | Indena S.P.A. | Methods of treatment using a soya extract |
DE19732855A1 (en) * | 1997-07-30 | 1999-02-18 | Indena Spa | Soya extract containing group B soya saponin(s) |
DE19732866C2 (en) * | 1997-07-30 | 1999-11-04 | Indena Spa | New soy extracts, their preparation, formulations based on them and their use for the prevention or treatment of pre-menopausal and post-menopausal symptoms |
US6607757B2 (en) | 1997-07-30 | 2003-08-19 | Indena S.P.A. | Soya extract, process for its preparation and pharmaceutical composition |
DE19732855C2 (en) * | 1997-07-30 | 1999-11-11 | Indena Spa | Special soy extract, its preparation, formulations containing it and their use for the prevention or treatment of cancer |
US6280777B1 (en) | 1997-07-30 | 2001-08-28 | Indena S.P.A. | Soya extract, process for its preparation and pharmaceutical composition |
US5855892A (en) * | 1997-09-19 | 1999-01-05 | Potter; Susan M. | Method for decreasing LDL-cholesterol concentration and increasing HDL-cholesterol concentration in the blood to reduce the risk of atherosclerosis and vascular disease |
EP0903143A3 (en) * | 1997-09-19 | 1999-05-06 | Protein Technologies International, Inc. | Use of daidzein for the manufacture of a medicament for incraesing HDL cholesterol levels |
EP0903143A2 (en) * | 1997-09-19 | 1999-03-24 | Protein Technologies International, Inc. | Use of daidzein for the manufacture of a medicament for incraesing HDL cholesterol levels |
US5952374A (en) * | 1997-09-29 | 1999-09-14 | Protein Technologies International, Inc. | Method for inhibiting the development of Alzheimer's disease and related dementias- and for preserving cognitive function |
EP1049451B1 (en) * | 1997-12-24 | 2005-11-30 | Novogen Research Pty. Ltd. | Use of compounds for protecting skin from uv induced immunosuppression |
EP1049451A1 (en) * | 1997-12-24 | 2000-11-08 | Novogen Research Pty. Ltd. | Compositions and method for protecting skin from uv induced immunosuppression and skin damage |
US6004558A (en) * | 1998-02-25 | 1999-12-21 | Novogen, Inc. | Methods for treating cancer with legume plant extracts |
WO1999043335A1 (en) * | 1998-02-25 | 1999-09-02 | Novogen Research Pty. Ltd. | Plant extracts and anti-cancer modalities involving the same |
EP1321146A2 (en) * | 1998-03-11 | 2003-06-25 | Endorecherche Inc. | Inhibitors of type 5 and 3 17beta-hydroxysteroid dehydrogenase and methods for their use |
EP1321146A3 (en) * | 1998-03-11 | 2004-06-02 | Endorecherche Inc. | Inhibitors of type 5 and 3 17beta-hydroxysteroid dehydrogenase and methods for their use |
US6132795A (en) * | 1998-03-15 | 2000-10-17 | Protein Technologies International, Inc. | Vegetable protein composition containing an isoflavone depleted vegetable protein material with an isoflavone containing material |
US6599536B1 (en) | 1998-03-26 | 2003-07-29 | Novogen Research Pty Ltd | Therapy of estrogen-associated disorders |
WO1999049862A1 (en) * | 1998-03-30 | 1999-10-07 | The University Of Mississippi | Isoflavones for treating giardiasis and malaria |
US6083553A (en) * | 1998-06-05 | 2000-07-04 | Protein Technologies International, Inc. | Recovery of isoflavones from soy molasses |
US6482448B2 (en) | 1998-07-16 | 2002-11-19 | Aaron Tabor | Soy formulations and their use for promoting health |
WO2000003684A2 (en) * | 1998-07-16 | 2000-01-27 | Aaron Tabor | Soy formulations and their use for promoting health |
EP1438900A1 (en) * | 1998-07-16 | 2004-07-21 | Aaron Tabor | Use of soy formulations in food compositions |
WO2000003684A3 (en) * | 1998-07-16 | 2000-04-20 | Aaron Tabor | Soy formulations and their use for promoting health |
WO2000016759A3 (en) * | 1998-09-17 | 2000-05-25 | Guido Schnyder | Genistein for the treatment of coronary heart disease and for the prevention of restenosis after percutaneous transluminal coronary angioplasty |
WO2000016759A2 (en) * | 1998-09-17 | 2000-03-30 | Guido Schnyder | Genistein for the treatment of coronary heart disease and for the prevention of restenosis after percutaneous transluminal coronary angioplasty |
US6703051B1 (en) | 1998-10-13 | 2004-03-09 | Solae, Llc | Process for separating and recovering protein and isoflavones from a plant material |
US6630178B1 (en) | 1998-11-25 | 2003-10-07 | Nutri Pharma Asa | Composition comprising soy protein, dietary fibres and a phytoestrogen compound and use thereof in the prevention and/or treatment of cardiovascular diseases |
US6509043B1 (en) | 1998-11-25 | 2003-01-21 | Nutri Pharma Asa | Composition comprising soy protein, dietary fibres and a phytoestrogen compound and use thereof in the prevention and/or treatment of pulmonary diseases |
WO2000056177A2 (en) * | 1999-03-22 | 2000-09-28 | Stewart And Lynda Resnick Revocable Trust | Pomegranate extracts and methods of using thereof |
WO2000056177A3 (en) * | 1999-03-22 | 2001-02-15 | Stewart & Lynda Resnick Trust | Pomegranate extracts and methods of using thereof |
US8221806B2 (en) | 1999-04-19 | 2012-07-17 | Stewart And Lynda Resnick Revocable Trust | Methods of using pomegranate extracts for causing regression in lesions due to arteriosclerosis in humans |
US8372454B2 (en) | 1999-04-19 | 2013-02-12 | Pom Wonderful Llc | Methods of making pomegranate compounds for the treatment of erectile dysfunction |
US8734868B1 (en) | 1999-04-19 | 2014-05-27 | Pom Wonderful, Llc | Methods of using pomegranate extracts for treating diabetes related atherosclerotic complications in humans |
US6387418B1 (en) | 1999-04-19 | 2002-05-14 | Stewart And Lynda Resnick Revocable Trust | Pomegranate extracts and methods of using thereof |
US6375993B1 (en) | 1999-04-19 | 2002-04-23 | Stewart And Lynda Resnick Revocable Trust | Pomegranate extracts and methods of using thereof |
US6361807B1 (en) | 1999-04-19 | 2002-03-26 | Stewart And Lynda Resnick Revocable Trust | Pomegranate extracts and methods of using thereof |
US7727563B2 (en) | 1999-04-19 | 2010-06-01 | Pom Wonderful, Llc | Methods of using pomegranate extracts for treating diabetes related atherosclerotic complications in humans |
US6669952B2 (en) | 1999-04-23 | 2003-12-30 | Solae, Llc | Composition containing isoflavone material and plant sterol for reducing LDL-cholesterol |
US6544566B1 (en) | 1999-04-23 | 2003-04-08 | Protein Technologies International, Inc. | Composition containing plant sterol, soy protein and isoflavone for reducing LDL cholesterol |
US6572876B2 (en) | 1999-04-23 | 2003-06-03 | Solae, Llc | Administering a composition containing plant sterol, soy protein and isoflavone for reducing LDL-cholesterol |
US7285297B1 (en) | 1999-04-23 | 2007-10-23 | Archer-Daniels-Midland Company | Method of reducing low density liproprotein cholesterol concentration |
US6579534B2 (en) | 1999-04-23 | 2003-06-17 | Solae, Llc | Composition containing soy hypocotyl material and plant sterol for reducing LDL-cholesterol |
WO2000064438A1 (en) * | 1999-04-28 | 2000-11-02 | Novogen Research Pty Ltd | Cardiovascular and bone treatment using isoflavones |
AU761047B2 (en) * | 1999-04-28 | 2003-05-29 | Novogen Research Pty Ltd | Cardiovascular and bone treatment using isoflavones |
US7432425B2 (en) | 1999-05-20 | 2008-10-07 | The Samuel Roberts Noble Foundation | Isoflavonoid methylation enzyme |
WO2000071736A1 (en) * | 1999-05-20 | 2000-11-30 | The Samuel Roberts Noble Foundation, Inc. | Isoflavonoid methylation enzyme |
US6878859B1 (en) | 1999-05-20 | 2005-04-12 | The Samuel Roberts Noble Foundation, Inc. | Isoflavonoid methylation enzyme |
US7488494B2 (en) | 1999-09-06 | 2009-02-10 | Novogen Research Pty Ltd. | Compositions and therapeutic methods involving isoflavones and analogues thereof |
US6500965B2 (en) | 2000-07-20 | 2002-12-31 | Linnea Sa | Dry extract which is rich in isoflavones in the form of aglycones and process for preparing the same |
US7045164B2 (en) | 2000-11-09 | 2006-05-16 | Cargill, Incorporated | Soybean processing |
WO2002055072A1 (en) * | 2001-01-16 | 2002-07-18 | Novogen Research Pty Ltd | Regulation of lipids and/or bone density and compositions therefor |
US7312344B2 (en) | 2001-03-08 | 2007-12-25 | Novogen Research Pty Limited | Dimeric isoflavones |
EP1401260A4 (en) * | 2001-06-13 | 2005-04-06 | Du Pont | A method for altering the isoflavonoid profile in the plant parts of an isoflavonoid-producing plant |
EP1401260A2 (en) * | 2001-06-13 | 2004-03-31 | E.I. du Pont de Nemours and Company | A method for altering the isoflavonoid profile in the plant parts of an isoflavonoid-producing plant |
WO2003074064A1 (en) * | 2002-03-04 | 2003-09-12 | Medana Pharma Terpol Gorup S.A. | Solid composition containing isoflavonoids for oral administration and method of obtaining same |
US9018247B2 (en) | 2002-07-24 | 2015-04-28 | Children's Hospital Medical Center | Compositions and products containing S-equol, and methods for their making |
US8668914B2 (en) | 2002-07-24 | 2014-03-11 | Brigham Young University | Use of equol for treating skin diseases |
US8048913B2 (en) | 2002-07-24 | 2011-11-01 | Australian Health & Nutrition Assoc. Ltd. | Compositions and products containing S-equol, and methods for their making |
US9408824B2 (en) | 2002-07-24 | 2016-08-09 | Children's Hospital Medical Center | Compositions and products containing S-equol, and methods for their making |
US9173866B2 (en) | 2002-07-24 | 2015-11-03 | Children's Hospital Medical Center | Compositions and products containing R-equol, and methods for their making |
US7960432B2 (en) | 2002-07-24 | 2011-06-14 | Children's Hospital Medical Center | Compositions and products containing S-equol, and methods for their making |
US7396855B2 (en) | 2002-07-24 | 2008-07-08 | Children's Hospital Medical Center | Compositions and products containing S-equol, and methods for their making |
US7468445B2 (en) | 2002-08-07 | 2008-12-23 | University Of Mississippi | Antigiardial agents and use thereof |
WO2004014886A1 (en) * | 2002-08-07 | 2004-02-19 | University Of Mississippi | Antigiardial agents and use thereof |
US8580846B2 (en) | 2002-10-29 | 2013-11-12 | Brigham Young University | Use of equol for ameliorating or preventing neuropsychiatric and neurodegenerative diseases or disorders |
US8450364B2 (en) | 2002-10-29 | 2013-05-28 | Brigham Young University | Use of equol for treating androgen mediated diseases |
US9089547B2 (en) | 2002-10-29 | 2015-07-28 | Brigham Young University | Use of equol for treating androgen mediated diseases |
US8153684B2 (en) | 2002-10-29 | 2012-04-10 | Colorado State University Research Foundation | Use of equol for treating androgen mediated diseases |
US9408825B2 (en) | 2002-10-29 | 2016-08-09 | Brigham Young University | Use of equol for treating androgen mediated diseases |
US9889116B2 (en) | 2002-10-29 | 2018-02-13 | Bringham Young University | Use of equol for treating androgen mediated diseases |
US10111855B2 (en) | 2002-10-29 | 2018-10-30 | Brigham Young University | Use of equol for treating androgen mediated diseases |
WO2007073908A1 (en) | 2005-12-29 | 2007-07-05 | Evultis S.A. | A process for the isolation of pharmacologically active principles of vegetable and animal origin |
US8263140B1 (en) | 2008-04-16 | 2012-09-11 | Pom Wonderful, Llc | Pomegranate based skin protectant and topical application |
WO2012004653A1 (en) * | 2010-07-07 | 2012-01-12 | Council Of Scientific & Industrial Research | Method for inhibition of nf-kb gene expression |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5830887A (en) | Health supplements containing phyto-oestrogens, analogues or metabolites thereof | |
Tew et al. | A diet high in wheat fiber decreases the bioavailability of soybean isoflavones in a single meal fed to women | |
JB et al. | The effects of phytoestrogens on bone | |
CA2287965C (en) | Treatment or prevention of menopausal symptoms and osteoporosis | |
WO1994023716A1 (en) | Method for treatment of menopausal and premenstrual symptoms | |
AU5316899A (en) | Soy formulations and their use for promoting health | |
US20020076455A1 (en) | Novel preparation of fiber, L-glutamine and a soy derivative for the purpose of enhancement of isoflavone bioavailability | |
WO2006042370A1 (en) | Hair and nail compositions and methods | |
AU777561B2 (en) | Health supplements containing phyto-oestrogen, analogues or metabolites thereof | |
AU2004224983A1 (en) | Health supplements containing isoflavones | |
US20080161385A1 (en) | Composition Inhibiting Sex Hormone-Binding Globulin | |
Baker | Phytoestrogens for menopausal women |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AT AU BB BG BR CA CH CZ DE DK ES FI GB HU JP KP KR KZ LK LU MG MN MW NL NO NZ PL PT RO RU SD SE SK UA US VN |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 252051 Country of ref document: NZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2136233 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1993909679 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 09602191 Country of ref document: US Ref document number: 08338567 Country of ref document: US |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWP | Wipo information: published in national office |
Ref document number: 1993909679 Country of ref document: EP |
|
WWG | Wipo information: grant in national office |
Ref document number: 1993909679 Country of ref document: EP |